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Prion is an infectious isoform of a normal cellular protein which is capable of converting 
the non-prion form of the same protein into the altrnative prion form. Mammalian prion 
protein PrP is responsible for prion formation (PrPSc) in mammals, causing a series of 
fatal and incurable prion diseases. (1) We constructed, for the first time, a two-component 
system to phenotypically monitor the conformational st tus of PrP in the yeast cells. In 
this system, the prion domain of Sup35 (Sup35N) wasfused to PrP90-230, and the initial 
formation of the PrPSc-like conformation stimulated prion formation of Sup35N, which in 
turn converted soluble Sup35 into the prion isoform, leading to a detectable phenotype. 
Prion-like properties of PrP were studied in this novel yeast model system. Additionally, 
we employed this system to study amyloidogenic protein Aβ42 aggregation in the yeast 
model.  
  
It has been suggested that the ability to form transmissible amyloids (prions) is 
widespread among yeast proteins and is likely intrinsic to proteins from other organisms. 
However, the distribution of yeast prions in natural conditions is not yet clear, which 
prevents us from understanding the relationship betwe n prions and their adaptive roles 
in various environmental conditions. (2) We modified and developed sequence and 
phenotype-independent approaches for prion detection and monitoring.  We employed 
these approaches for prion-profiling among yeast strains of various origins.    
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(3) Lastly, we found a prion-like state [MCS+] causing nonsense suppression in the 
absence of the Sup35 prion domain. Our results suggested that [MCS+] is determined by 
both a prion factor and a nuclear factor. The prion- elated properties of [MCS+] were 





                                                                                                                              
                                                                                                                                
 








1-1 Prions and amyloids 
A prion (proteinaceous infectious particle) is an infectious isoform of a normal cellular 
protein which is capable of converting the non-prion f rm of the same protein into the 
alternative prion form (Figure 1-1). Prion conversion is always associated with a 
conformational change of the secondary structure of the native protein which forms a 
highly a stable β-sheet-rich structure termed “amyloid”.  Prions are self-propagating 
amyloids and the β-sheet-rich structure can be precisely reproduced and transmitted 
solely by the prion protein itself.  The prion concept was first proposed by Prusiner in 
1982 (Prusiner et al., 1982), and explains a series of mammalian neurodegenerative 
disorders caused by an abnormal isoform of the prion pr tein PrP. Prions have also been  
identified in fungi, although the responsible proteins are not homologous in sequence to 
mammalian PrP.       
  







Figure 1-1. The prion model: Prion is an infectious or heritable agent made only f 
protein. A prion protein can convert a non-prion protein of the same amino acid sequence 
into a prion 
.  
 
1-2 Prion diseases  
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Prion diseases, also known as transmissible spongiform encephalopathies (TSE), are fatal 
neurodegenerative disorders which occur in humans and nimals (Table 1-1). No 
treatments for prion diseases are currently available. Prion diseases are characterized by 
the transformation of a cellular prion protein of normal conformation, PrPC, into a β-
sheet-rich and protease-resistant conformation, PrPSC.  
 
Affected species                                                Diseases
Sheep, goat                                    Scrapie
Cattle                                              Bovine spongiform encephalopathy (“mad cow” disease)
Deer, elk, mule, moose                  Chronic wasting disease
Mink                                                Transmissible mink encephalopathy   
Feline                                              Feline spongiform encephalopathy 
Human                                            Creutzfeldt–Jakob disease (CJD), Gerstmann–Sträussler–Scheinker
syndrome (GSS), Fatal familial insomnia (FFI), Kuru
Table 1-1. Prion diseases in mammals
 
 
Scrapie was the first recognized prion disease and affects sheep and goats (Kimberlin et 
al., 1981). Scrapie has been recognized in European countries for centuries and is present 
worldwide. Other identified prion diseases which affect animals include bovine 
spongiform encephalopathy (BSE) (Wells et al., 1987), chronic wasting disease of mule 
deer and elk (Williams and Young , 1980), transmissible mink encephalopathy (Marsh et 
al., 1992), feline spongiform encephalopathy of domestic cats (Wyatt et al., 1991), and 
spongiform encephalopathies of a number of zoo animls (Jeffrey and Wells et al., 1988; 
Kirkwood et al., 1990)  
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The human prion diseases have been classified into Creutzfeldt-Jakob disease (CJD), 
Gerstmann-Sträussler-Scheinker syndrome (GSS), fatal insomnia (FI) and kuru.  Human 
prion diseases occur via sporadic, acquired, and inherited ways, and the most common is 
the sporadic form of CJD, which accounts for approximately 85% of all cases (Will et al., 
1996). Sporadic CJD occurs in all countries with a random case distribution and an 
annual incidence of ~one per million. The pathogenesis of sporadic CJD remains unclear, 
and epidemiological studies have failed to identify any specific risk factors for sporadic 
CJD.  Characteristically, the disease affects elderly individuals with a peak onset at 60–
69 years of age, with a wide age range from 14 to over 90 years (Brown et al., 1986).    
 
About 10-15% of human prion disease is inherited, and so far all cases have been 
associated with mutations in the PrP coding gene (PRNP) (Collinge et al., 1997; Collinge 
et al., 2001). To date, GSS has only been described in association with PRNP gene 
mutations and is inherited in an autosomal dominant manner. Histologically, the hallmark 
of GSS is the presence of multicentric PrP-amyloid plaques, while in most cases of CJD 
and FI, PrPSc accumulates in brain parenchyma without significant myloid deposition.  
Acquired prion diseases include iatrogenic CJD and kuru and arise from accidental 
exposure to human prions through medical or surgical procedures or participation in 
cannibalistic feasts.  
 
To understand the prion mechanism, two major issues ne d to be addressed: the initiation 
of prion formation and prion propagation. Unfortunately, neither of them is well 
understood. The initial prion conversion process remains a mystery. In fact de novo 
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formation of a prion is a rare event, and the majority of prion-associated diseases are 
sporadic.  Although a number of disease-promoting mutations in PrP have been identified 
(van der Kamp et al., 2009; Solomon et al., 2009), systematic studies of the mechanisms 
by which mutations influence a prion are difficult due to a high complexity of the 
experimental animal models and long incubation times employed.  Nevertheles, prion 
propagation, in other words, the conformational transmission from PrPSc to PrPC, is being 
extensively studied using animal models.  The likely mechanism of prion propagation is 
immobilization of the monomeric protein into amyloid genic polymers, accompanied by 
conversion into the β-sheet-rich conformation (Lansbury et al., 1995).   
 
Besides prion diseases, there are other human neurodegenerative diseases associated with 
formation of amyloids or amyloid-like polymers (Aguzzi et al., 2010). Two well known 
amyloidosis diseases are Huntington’s disease (HD) and Alzheimer’s disease (AD). 
Huntington’s disease is an inherited neurodegenerativ  disorder caused by polyglutamine 
(polyQ) expansions in the huntingtin (Ht) protein, which leads to formation of fibrous 
polymers (Shao et al., 2007). Alzheimer's disease is another fatal neurodegenerative 
disease, affecting approximately 50% people by age 85 (Kidd et al., 2008). It is 
associated with accumulation of polymers of the amyloid β (Aβ) peptide, produced by 
proteolytic cleavage of amyloid protein precursor (APP) (Goedert et al., 2006; Roberson 
et al., 2006). Less that 1% of AD cases are associated with mutations; the rest are 
sporadic. Although AD is not known to be infectious from person to person, transmission 
of Aβ amyloids by injection has been observed in experimental models (Kane et al., 
2000).   




In summary, human prion diseases and other amyloidosis diseases are fatal and incurable. 
These diseases occur sporadically and their incidene increases with age.  These diseases 
pose an enormous threat to human health and limit the human life span. It is very 
important to study the mechanism of prion and amyloid f rmation in order to achieve 
treatment or disease prevention.      
 
1-3 Mammalian prion protein  
Compelling evidence demonstrate that TSEs are transmitted by the mammalian prion 
protein (PrP) in an abnormal PrPSc (prion) conformation. Propagation occurs by 
converting the PrPC cellular protein of the same sequence into a prion (Prusiner et al., 
1982; Prusiner et al., 1998). Compared with wild type mouse, the PrP knockout mouse 
showed a complete resistance to prion disease and did not replicate prions (Bueler et al., 
1993).   
  
Prion protein PrP is highly conserved in mammals and may be present in all vertebrates. 
It is expressed during early embryogenesis and is found in most tissues in adults (Manson 
et al., 1992). However, the highest level of expression is detected in the central nervous 
system, and particular, in association with synaptic membranes. As a 
glycosylphosphatidylinositol (GPI) anchored cell-surface glycoprotein, it has been 
speculated that prion protein may have a role in cell adhesion or signaling processes, but 
its precise cellular function remains unclear.  
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Prion protein encoded by a single gene, PRNP, consists of about 250 residues (254 aa for 
mouse PrP) (Figures 1-2). With posttranslational processing, the 22 aa N-terminal signal 
peptide is removed, and the 23 aa C-terminal peptid is replaced with a GPI-anchor 
peptide. There is an unstructured copper binding octarepeats in the N-terminal region of 
PrP residues which is rich in glycine (Prusiner et al., 1998). NMR studies of the 
remaining protein (residues 90-230) show that the N-terminus is largely unstructured 
(Donne et al., 1997), and the C-terminus is an ordered globular domain. The structures of 
the C-terminal region of PrPC from three species (mouse, hamster, and human) show that 
they each consist of three α helices and two short antiparallel β-strands (Riek et al., 1996; 
Riek et al., 1997; James et al., 1997; Donne et al.,1997; Zahn et al., 2000).  The Mouse 
PrP90–230 region is essential and sufficient for prion transmission, while the N-terminus 
90-120 region is especially required for prion formation. (Peretz et al., 1997)  The prion 
form PrPSc has a highly stable β-sheet-rich conformation, which distinguishes it from the 
α-helix-rich, protease-sensitive PrPC (Pan KM, 1993).  Electron microscopy study 
suggests a parallel β-helix structure in PrPSc (Wille et al., 2002).  
 
                     
1      22        50          90      120                        230    254
Secretory
signal peptide
GPI anchor               
peptide
Octa-
peptide       





Figure 1-2: Structural and functional organization of mouse prion protein PrP  The 
PrP protein consists of N terminal secretory signal peptide which is removed after 
maturation, octa-peptide repeats, and C terminal glycosylphosphatidyl inositol (GPI) 
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anchor peptide. The region emcompassing redisues 90-230 is essential and sufficient for 
the prion conversion and transmission.  Numbers correspond to amino acid positions.   
 
 
1-4 Yeast Prions 
A numbers of prions have been found in yeast (in most cases Saccharomyces cerevisiae) 
which share many similarities with mammalian prions (Chien et al., 2004) (Table 1-2). 
Yeast prions manifest themselves as non-Mendelian heritable states transmitted via the 
cytoplasm, and are usually associated with a partial loss of the cellular function of a 
prion-forming protein. This partial loss of cellular function has enabled researchers to 
develop rapid and simple prion detection tools. Because of the ease of genetic 
manipulation and fast growth rate of yeast, yeast prions serve as a good model for the 
study of prions.  
 
Protein        Prion state      Non-prion state              Cellular function
Sup35 [PSI+] [psi-] Translation termination factor
Ure2 [URE3] [ure3-0] Regulator in nitrogen metabolism
Rnq1 [PIN+] [pin-] Unknown
Swi1 [SWI+] [swi-] Chromatin remodeler
Mca1 [MCA+] [mca-] Metacaspase
Cyc8 [OCT+] [oct-] Transcriptional corepressor
Mot3 [MOT3+] [mot3-] Transcriptional repressor
Table 1-2. Proven yeast prions
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As one of the most extensively studied yeast prions, [PSI+] is the prion isoform of 
translational termination factor Sup35 (eRF3) (Cox et al., 1980, True et al., 2000). Sup35 
protein is essential for cell viability, and it works with Sup45 to indentify stop codons and 
to terminate translation. Prion conversion of Sup35 results in a decreased translation 
termination function, due to its conformational change and amyloid formation.  Another 
well characterized yeast prion is [URE3], whose functional isoform is Ure2, a 
posttranslational regulator in the nitrogen metabolism pathway (Shorter et al., 2005). The 
prion formation of [URE3] causes cells to constitutively utilize poor nitrogen sources. 
The [PIN+] prion was initially detected by its ability to promote de novo formation of the 
[PSI+] prion (Derkatch et al., 1997) and was then discovered to be an isoform of the Rnq1 
protein of unknown cellular function called Rnq1 (Sondheimer and Lindquist, 2000, 
Derkatch et al., 2001).    
 
There have been several more yeast prions identified in recent years, including [MOT3+], 
[SWI+], [OCT+] and [MCA+]. [MOT3+] is a prion formed by the transcription factor Mot3, 
an environmentally responsive regulator of yeast cell wall composition and pheromone 
signaling (Abramova et al., 2001). Cells with the [MOT3+] prion show increased 
resistance to certain cell wall stressors. [SWI+] and [OCT+] are formed by the globally 
acting transcriptional regulators, Swi1 and Cyc8, respectively (Du et al., 2008; Patel et al., 
2009). [SWI+] cells are resistant to the microtubule disruptor, benomyl; and [OCT+] 
induces flocculation, a growth form that has been shown to protect cells from various 
stresses. [MCA+] is a prion formed by Mca1, a metacaspase which has been proposed to 
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be involved in yeast programmed cell death processes (Nemecek et al., 2009). The 
physiological consequence of the [MCA+] prion is not yet clear.    
  
Yeast prion proteins contain prion domains (PrDs) which are responsible for both in vivo 
prion formation and propagation, and in vitro amyloid aggregation (Chernoff et al., 2004). 
For all the proven yeast prions (Table 1-2), the prion domains are glutamine (Q) and 
asparagine (N)- rich, and are always separate from the domains responsible for the major 
cellular function of  the respective proteins. Unlike the mammalian prion PrPSc, yeast 
prions are not pathogenic. Prion infected yeast cells do not show apparent growth defects 
compared with wild-type, and they show even better growth in some unfavorable 
conditions. Thus it has even been proposed that yeast prions might have some adaptative 
roles in evolution (True et al., 2000, Chernoff et al., 2007; Chernoff et al., 2008).    
 
1-5 Sup35 and the [PSI+] prion   
Sup35 is the protein responsible for the [PSI+] prion; it contains 685 amino acids and can 
be divided into three domains (Figure 1-3 A). The 123 residue N-terminal domain (N) is 
the prion domain (PrD), which is essential for prion f rmation and propagation (Figure 1-
3 B). The Sup35 N domain contains a Q/N rich stretch and five imperfect oligopeptide 
repeats. Experimental data suggest that [PSI+] formation is driven primarily by the amino 
acid composition, but not by the sequence, of the Sup35 prion domain. In addition, 
Sup35p oligopeptide repeats are not required for prion maintenance (Ross et al., 2005; 
Toombs et al., 2010).  The prion domain is dispensable for the cellular function of normal 
Sup35 protein.   
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Figure 1-3. Structure of Sup35 and Sup35 prion fiber . N, M and C refer to Sup35N, 
Sup35M and Sup35C regions respectively. Numbers correspond to amino acid positions. 
A- Structural and functional organization of the Sup35 protein. B- Structure of the 
Sup35N region (prion domain). C- Structure of the Sup35 prion fiber. Sup35N domains 
form the core of the fiber, Sup35C (and possibly M) domains are exposed on the side. 
The ends of the fiber are active sites for immobilization of new sup35 molecules 
 
 
The middle domain (M) (aa 124–253) is highly charged and is dispensable for both cell 
viability and [PSI +] propagation (Derkatch et al., 1996; Kushnirov et al., 1990; Ter-
Avanesyan et al., 1993). The M region is thought to promote protein solubility. In vivo, 
the fragment containing the Sup35N and M regions (NM) is soluble in yeast cells with no 
Sup35 prion ([psi-]). In contrast, Sup35N alone is insoluble in the[psi-] strain (Paushkin 
et al., 1996). The C-terminal domain (C) (aa 254–685) of Sup35 is the functional domain, 
which is responsible for the translation termination function. It is dispensable for [PSI +] 
induction and propagation but is essential for viability (Derkatch et al., 1996; Ter-
Avanesyan et al., 1994).  




The prion conversion of Sup35 is associated with exensive conformational change of the 
prion domain to form a β-sheet enriched structure. Prion domains are connected together 
via β – β interactions and form the axis of the amyloid fiber (Krishnan et al., 2005; 
Nelson et al., 2005). The M and C domains are exposed n the side of the fiber and may 
retain the proper fold (Figure 1-3 C). The amyloid fiber is highly ordered and very stable, 
and it is protease-resistant and detergent insoluble (Kryndushkin et al., 2003; Bagriantsev 
et al., 2004).   
 
1-6  Nonsense suppression system is used to assay [PSI+] 
 
In the [PSI+] yeast strain, most of the Sup35 protein is sequester d as an amyloid, which 
in turn decreases its normal cellular function in translation termination. Based on this 
phenotypic character, a nonsense suppression assay is used to detect the [PSI+] prion. 
(Figure 1-4) (Chernoff et al., 2000; Derkatch et al., 1996) 
 
For the nonsense mutation allele ade1-14 UGA, the [PSI
+] strain has partial translational 
readthough, caused by the decreased translation termination function of Sup35. Therfore, 
there is still adenine produced and [PSI+] cells can grow on the synthetic medium lacking 
adenine (-Ade).  In [psi-] cells, the nonsense mutation is not suppressed and cells can not 
grow on –Ade media. Also [psi-] colonies show a red color on rich YPD medium while 
[PSI+] colonies show a white color.  





















Figure 1-4. Nonsense suppression system is used to assay [PSI+]  In [PSI+] strain, 
nonsense mutation ade1-14 UGA was suppressed, cells can grow on –Ade medium sicnce 
adenine was produced. In [psi-] strain no functional adenine was produced, cells can not 
grow on –Ade medium. [PSI+] colonies show white color on YPD medium, while [psi-] 
colonies show red color on YPD medium.  
 
 
1-7  De novo prion induction in yeast 
 
Transient overproduction of Sup35 protein or its prion domain can induce de novo 
appearance of [PSI+] prion in a [psi-] cell (Chernoff et al., 1993), but the induction is only 
efficient in the presence of other Q/N rich yeast prions such as [PIN+] (Derkatch et al., 
1997; Derkatch et al., 2000). The increased amount of Sup35 protein presumably 
enhances the chance that a prion seed will form de novo, and the [PIN+] amyloid is 
proposed to  provide an initial nuclei facilitating [PSI+] appearance (Figure 1-5) (Bradley 
et al., 2002). Notably, the [PIN+] prion is only needed for [PSI+] induction, and it is 
dispensable for [PSI+] propagation (Derkatch et al., 2000).    














































 Figure 1-5. De novo induction of [PSI+] by excess Sup35 or Sup35N. Overproduction 
of Sup35 or Sup35N can induce d  novo formation of [PSI+] facilitated by another prion 
(e. g. [PIN+], prion isoform of Rnq1). The [PSI+] induction is not efficient without other 
pre-formed prion.    
 
 
1-8  Role of molecular chaperone Hsp104 in prion propagation  
Molecular chaperones are proteins which can recognize and bind to misfolded 
polypeptides and facilitate their folding into native states that are specified by their 
primary sequences (Wickner et al., 1999). Hsp104 is a heat shock protein which is 
required for induced thermotolerance (Sanchez and Li quist, 1990; Parsell et al., 1994). 
However, this chaperone is also important for yeast prion propagation.  
 
The expression level of Hsp104 is crucial for [PSI+] propagation; either overproduction 
or deletion of Hsp104 will eliminate the [PSI+] prion (Figure 1-6) (Chernoff et al., 1995; 
Patino et al., 1996; Newman et al., 1999). Notably, only transient overproduction of 
Hsp104 is sufficient to eliminate the [PSI+] prion, and when the Hsp104 level is returned 
to normal, the prion state does not reappear.  
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The mechanism of Hsp104 curing effects is not yet cl ar. One model suggests that 
Hsp104 can break the [PSI+] amyloid fibers into smaller prion “seeds”, which would 
more efficiently promote prion conversion of newly s nthesized Sup35  (Kushnirov and 
Ter-Avanesyan, 1998; Paushkin et al.,1996). Depletion of Hsp104 results in insufficient 
prion “seeds” as well as larger amyloid fibers, which would be inefficiently transmitted to 
daughter cells. Conversely, excess Hsp104 may disaggregate the amyloid fiber to such a 
high degree that all or most of the Sup35 is disassociated into monomer and can be easily 
refolded into the native conformation or be degraded with the help of the 
Ubiquitin/Proteasome system (Kushnirov and Ter-Avanesyan, 1998; Patino et al., 1996) 










No new prion seeds, 
aggregates grow too large





Figure 1-6. Model of Hsp104 modulated [PSI+] propagation and elimination.  Excess 
Hsp104 will disaggregate the prion polymers into monomers. The prion monomers will 
either be refolded into soluble Sup35 facilitated by other chaperon systems such as 
Hsp70/Hsp40, or be degraded via ubiquitin-proteasome system. On the other hand, if 
Hsp104 is eliminated or inactivated, the prion aggre ate may not be sheared properly and 
can not initiate new round of polymerization; the prion aggregate may also grow too big 
to transmit efficiently to the daughter cells.    
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Hsp104 is also required for the propagation of other yeast prions, such as [URE3] and 
[PIN+]. Interestingly overproduction of Hsp104 does not eliminate [URE3] (Moriyama et 
al., 2000) or [PIN+] (Derkatch et al., 1997; Sondheimer and Lindquist, 2000).  The 
activity of Hsp104 can be inhibited by millimolar concentrations of guanidine 
(Grimminger et al., 2004), which is therefore employed as a yeast prion-curing agent 







































A YEAST MODEL FOR PRION-RELATED PROPERTIES OF 




2-1 Introduction:  
Prion diseases are fatal and presently, incurable. Both incubation periods and the late 
appearance of symptoms make it difficult to study the prion mechanism directly in 
animal models. Also, animal-based infectivity assay re laborious and difficult to apply 
to initial prion formation, which occurs at low frequency. In vitro systems have been 
developed to study the propagation of the protease-re istant PrPres conformation 
(resembling PrPSc) (Caughey et al., 1995; Castilla et al., 2005).  However their role 
remains limited since the in vitro conditions can not reproduce those existing in the cell.   
 
Yeast prions have been extensively studied, and the availability of powerful genetic 
approaches using the yeast model led to rapid progress in the prion field. However, yeast 
prion proteins are non-homologous to mammalian PrP and to other mammalian 
amyloidogenic proteins. Ultimately, mammalian PrP has been studied in the yeast model. 




One of the pioneering works to study the aggregation pr perties of mammalian PrP in the 
yeast system was done by Ma and Lindquist (Ma and Li quist, 1999). They found that a 
PrPSc-like conformation could be generated by the high-leve  expression of mouse PrP23-
231 in the yeast cytoplasm. The PrP
Sc-like structure is detergent insoluble and proteinase K 
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resistant (two hallmarks of PrPSc), and the proteinase K resistant fragment of PrP from 
yeast is the same as that from PrPSc. In mammalian cells PrPC is cotranslationally 
translocated into the secretory pathway, of which two features distinguish it from 
cytoplasm: N-linked glycosylation and the oxidation f sulphydryl bonds (Weissmann et 
al., 1994; Prusiner et al., 1998). Thus, the de novo formed PrPSc-like conformation in the 
yeast cytoplasm may be due to the less glycoylated nd greater reducing environment. 
This hypothesis is supported by the finding that blocking glycosylation and providing a 
reducing environment promotes conversion of PrPC to a PrPSc-like form in mammalian 
cells (Ma and Lindquist, 1999). Further studies have revealed that the AGAAAAGA 
palindrome within the N-terminal region of PrP (aa 112-119) is crucial  for PrP to adopt 
the PrPSc-like conformation in the yeast cytoplasm, as well as for prion propagation in 
prion infected mammalian cells (Norstrom et al., 2005).  In the following study, it was 
found that PrP partially purified from the yeast cyoplasm can form amyloid fiber-like 
structures, and the PrPSc-like conformation is able to convert normal PrPC from mouse 
brain homogenate to a proteinase K-resistant conformation in vitro (Yang et al., 2006). 
These results suggest that the yeast originated PrPSc-like conformation has a self-
propagating property similar to that of a prion. 
 
Other mammalian amyloidogenic proteins have also been t sted in the yeast model 
system.  Aβ42 and expanded polyglutamine repeats, 2 protein/peptides responsible for 
Alzheimer’s disease and Huntington’s disease, respectively, were tagged with green 
fluorescent protein (GFP) and expressed in the yeast cytoplasm. Both can form 
aggregates spontaneously (Caine et al., 2007; Krobitsch and Lindquist, 2000; Meriin et 
18                                                                                                                                                     
 
 
al., 2002). Also, a chimeric Aβ42-Sup35 protein was constructed by replacing most or the 
entire Sup35 prion domain with Aβ42, and was tested in the yeast model system. It was 
found that the chimeric protein can form SDS stable oligomers, and the translation 
termination function of Sup35 is disturbed, presumably caused by the Aβ42 aggregation 
(Bagriantsev and Liebman, 2006; von der Haar et al., 2007).      
 
The major obstacle for monitoring PrPSc formation in non-mammalian environments has 
been a lack of reliable phenotypic detection assays. Biochemical techniques are not 
sufficient for differentiation between the amyloidogenic complexes and other forms of 
aggregates. In this work, we attempt to overcome this obstacle by employing a [PSI+] de 
novo induction system to monitor the formation of the PrPSc-like conformation. 
Overproduction of Sup35 or Sup35N can induced de novo [PSI+] formation, in the 
presence of other yeast prions such as [PIN+]. Previous results showed that the fusion of 
Sup35 or Sup35N to the expanded polyQ stretch, associated with HD (~50Q or more), 
enables overproduction of the chimeric construct to induce [PSI+] in the [pin-] strain 
(Goehler et al., 2010). Based on this finding, we constructed, for the first time, a two-
component system to phenotypically monitor the conformational status of PrP in the 
yeast cell. In this system, Sup35N was fused to PrP90-230, and the initial formation of 
PrPSc-like conformation stimulated prion formation of Sup35N, which in turn converted 
soluble Sup35 into [PSI+], leading to a detectable phenotype. Prion-like prope ties of PrP 
were studied in this novel yeast model system. Additionally, we employed this system to 
study Aβ42 aggregation in the yeast model, and, potentially, other amyloidogenic 
proteins could be examined.   





The main goal of this work is to establish a yeast-based model for studying the 
mechanism of prion and amyloid formation by mammalian proteins. The mechanism of 
the prion-inducing effect of mammalian PrP in yeast was investigated. The amino acids 
sequence elements or chemical compounds influenceing the prion inducing ability of 
mammalian PrP can be screened in this yeast-based sy tem, which will help us develop 
the anti-prion or anti-amyloid therapeutic treatments.    
 
  






All S. cerevisiae yeast strains used in this chapter are listed in table 2-1. The most 
commonly used set of isogenic strains in these studies are derived from the strong [PSI+ 
PIN+] diploid parent GT81 (Chernoff et al., 2000). GT81 is an autodiploid that is 
heterozygous by the MAT locus and homozygous for all other genes. GT81-1C is a
haploid, meiotic segregant derived from GT81. GT409 is a [psi-pin-] strain obtained by 
curing GT81-1C with GuHCl, while GT159 is [psi-PIN+] strain obtained by curing [PSI+] 
from GT81-1C with excess Hsp104.  GT564 is a [psi-] ∆rnq1 strain obtained by 
disrupting the RNQ1 gene from GT159. GT953 is a cytoduction recipient strain derived 
from 1B-D910 (MATa ade1-14SC his3 leu2 trp1 ura3 cyh
R kar1-1 [rho- psi- pin-]), kindly 
20                                                                                                                                                     
 
 
provided by A. Galkin (St. Petersburg University, Russia), with the sup35::HIS3 
deletion on the chromosome and containing a plasmid expressing Sup35 [SUP35 LEU2].   
 
MATa ade1-14 his3Δ (or 11,15) lys2 ura3-52 leu2-3,112 trp1 
sup35::HIS3  [CEN LYS2 SUP35] 
[PSI+]GT1535
MATa ade1-14SC his3Δ leu2-3,112 trp1-289 ura3 kar1 cyhR sup35::HIS3 [rho-]
[CEN LEU2 SUP35SC]
[psi-PIN+]GT953
MATa ade1-14SC his3-Δ200 lys2 leu2-3,112 trp1-Δ, ura3-52 ,rnq1 Δ::HIS3[psi-]GT564
MATa ade1-14SC his3-Δ200 lys2 leu2-3,112 trp1-Δ ura3-52 [psi-][PIN+][psi-PIN+]GT159
MATa ade1-14SC his3-Δ200 lys2 leu2-3,112 trp1-Δ ura3-52 [psi-pin-]GT409










Plasmids used and constructed in this study are listed and briefly described in table 2-2. 
All PCR-generated fragments were verified by sequencing.  
 
pcDNA3.1 (+) plasmids containing N-PrP90-230, PrP90-230 ,  NM-PrP90-230 , M-PrP90-230 ,  
NM-HA constructs were kindly provided by I. Vorberg. To express them in yeast, the 
constructs were excised with BamHI and XbaI/SacI and the desired fragment was put 
under the copper inducible promoter in vector pMCUP1. The resulting plasmids are: 
pMCUP1-N-PrP90-230, pMCUP1-PrP90-230, pMCUP1-NM-PrP90-230, and pMCUP1-M-
PrP90-230 and pMCUP1-NM-HA respectively.  
  
21                                                                                                                                                     
 
 
pMCUP1-N-PrP∆90-119 was constructed based on the NM-PrP∆90-119 fragment in 
plasmid pcDNA3.1 (+), from I. Vorberg. The NM-PrP∆90-119 fragment was cut out with 
BamHI and XbaI, and inserted into pMCUP1 vector, and then the NM fragment was 
removed with EcoRI and replaced with Sup35N.  
  
Plasmids pMCUP1-N-PrP∆160-230 and pMCUP1-N-PrP∆172-230 were constructed in 
the following way. N-PrP90-159 and N-PrP90-171 were PCR amplified from pMCUP1-
N-PrP90-230, adding BamHI and XbaI restriction sites to the end of the fragment. The 
common forward primer was: ATTAGGATC CGTCGCCACCATGTCC. The reverse 
primer for N-PrP∆160-230 was 
TAATTCTAGATCATTGGTTAGGGTAGCGGTACATG. The reverse primer for N-
PrP∆172-230 was: TAATTCTAGATCACTGGTTGCTGTACTGATCCACTGG. Those 
two DNA fragments were then digested with BamHI and XbaI and inserted into 
pMCUP1 under the CUP1 promoter. 
   
The pcDNA3.1 (+) plasmid containing the human Aβ42 gene was kindly provided from 
K.E. Ugen lab (Kutzler et al., 2006). Plasmid pMCUP1-N-Aβ42, expressing the chimeic 
protein N-Aβ42 was constructed in the following way. The open rading frame (ORF) 
region of Aβ42 was PCR amplified using the primers  
CAAGAATTCGATGCAGAATTCCGACATGAC and TTGTCTAGATTACGCTAT 
GACAACACCGCC. EcoRI and XbaI restriction sites are dded on the ends. The Aβ42 
fragment was then inserted into pcDNA3.1 (+) and liked with SUP35N by EcoRI. Then 
the SUP35N-Aβ42 fragment was cut with BamHI and XbaI and inserted into pMCUP1 
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under the CUP1 promoter. Plasmid pMCUP1-NM-Aβ42 was constructed by cutting 
SUP35N in pMCUP1-N-Aβ42 with EcoRI and replacing with SUP35NM.  The plasmid 
pMCUP1-NM-Aβ42TM was constructed using plasmid pMCUP1-NM-Aβ42 and 
generating the triple mutations F19S/F20S/I31P in the Aβ42 portion (triple mutations 
were generated by Emory University facilities).   
 
The plasmids pMCUP1-Sup35N-HA and pMCUP1-N-PrP90-230-HA were constructed in 
the following way. Sup35N and N-PrP90-230 were each amplified from plasmid pMCUP1-
N-PrP90-230, adding the HA tag on the C-terminal end. The common forward primer, 
containing the BamHI site, was: GCGTGGATCCGTCGCCACCATGTCC. The reverse 
primer, containing the SacI site, for Sup35N-HA was: AGTCGAGCTCTCAAGCGT 
AATCTGGTACGTCGTATGGGTAACCTTGAGACTGTGGTTGGAA. The rev rse 
primer, containing the SacI site, for PrP90-230-HA is: AGTCGAGCTCTCAAGCGT 
AATCTGGTACGTCG TATGGGTAGGATCTT CTCCCGTCGTAATA. The two DNA 
fragments were digested with BamHI and SacI and inserted into pMCUP1 vector under 
the CUP1 promoter.  
 
































SourcePromoter Yeast markerProteinPlasmid name
Table 2-2: Plasmids used in this study





Antibodies and their corresponding dilution rates are listed in table 2-3.   
 









Source Dilution rate Secondary antibodyDilution rateAntibody





Molecular biology techniques 
 
Standard protocols were used for DNA electrophoresis, restriction digestion, ligation, and 
bacterial transformation (Sambrook et al., 2001). Enzymes were purchased from New 
England Biolabs.   
 
QIAGEN Gel Extraction protocol  
 
Fragments of DNA generated by restriction digest or PCR reaction were separated using 
standard DNA electrophoresis (Sambrook and Russel, 2001). DNA bands corresponding 
to desired products were identified using a UV transilluminator (Fischer Biotech 312nm 
Variable Intensity Transilluminator) and bands were xcised from EtBr-stained gels using 
a scalpel. Separation of DNA from gel was achieved using the QIAquick Gel Extraction 
Kit and protocols supplied by the manufacturer, QIAGEN.  
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E.coli plasmid DNA isolation 
 
Small-scale plasmid DNA isolation was performed using the boiling prep method 
(Sambrook et al., 2001). Briefly, sterile wooden toothpicks were used to collect cells 
which were resuspended in STET buffer (5% Triton X-100, 8% sucrose, 20 mM 
ethylenediaminetetraacetic acid (EDTA), 50 mM Tris-HCl, pH 8.0) with lysozyme added 
to a final concentration of 1mg/ml. Suspensions were boiled for 90 seconds, followed by 
centrifugation at 16,000 g for 15 minutes. The viscous pellets were removed using sterile 
toothpicks, and DNA in the remaining supernatant was precipitated with isopropanol at -
20 ºC for 30 minutes. Precipitated DNA was collected by centrifugation at 16,000 g for 
10 minutes, washed with 70 % ethanol, dried thoroughly, and was resuspended in 
TE+RNase (10 mM Tris-HCl, 1 mM EDTA, 0.1 mg/ml RNase, pH 7.4). 
 
For large-scale isolation of plasmid DNA, sterile wooden toothpicks were used to collect 
cells from a quarter of the petri dish, and cells were resuspended in 200 µl of Solution I 
(25 mM Tris-HCl, 10 mM EDTA, 0.9% glucose, 2 mg/ml lysozyme, pH 8.0). 
Suspensions were incubated for 10 minutes, followed by adding 400 µl of Solution II (0.2 
M NaOH, 1% sodium dodecyl sulfate (SDS)). The mixtures were incubated on ice for 15 
minutes before 300 µl of Solution III (5 M CH3COONa – 3 M Na, 5 M acetate, pH 4.8) 
was added, and the mixtures were incubated on ice for another 30 minutes. Cell debris 
was pelleted at 16,000 g for 15 minutes. The supernatant was moved to another tube that 
contains 600 µl isopropanol and mixed well. The mixtures were incubated for 20 minutes. 
Precipitated DNA was collected by centrifugation at 16,000 g for 15 minutes, washed 
with 70 % ethanol, dried thoroughly, and resuspended in 200 µl of TE+RNase. 
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Suspensions were incubated at 37 ºC for 30 minutes, followed by adding 200 µl of 9 M 
lithium chloride (LiCl) and incubating at -20ºC for 20 minutes. The mixtures were 
pelleted at 16,000 g for 10 minutes, and supernatant was moved to another tube 
containing 800 µl of 95 % ethanol. DNA was precipitated for 40 minutes, and collected at 
16,000 g for 10 minutes. DNA pellet was washed with 70 % ethanol and dried thoroughly. 
Finally, dry pellets were resuspended in 30-50 µl of 10 mM Tris-HCl, pH 8.0. 
 
E. coli competent cells preparation 
 
The DH5α E. coli strain was inoculated into 100 ml of SOB (20 g/l Bactotryptone, 5 g/l 
Yeast Extract, 0.584 g/l NaCl, 0.186 g/l KCl and 5 ml/l 2 M Mg2+ was added after 
autoclaving). The culture was incubated in a 37 ºC shaker until an OD550 reached 0.45 to 
0.55. Cells were incubated on ice for 15 minutes, and were collected by centrifugation at 
2,000 g for 10 minutes at 4 ºC. Cells were resuspended in 33 ml of RF1 (100 mM 
Rubidium chloride (RbCl), 50 mM Manganese chloride (MnCl), 30 mM Potassium 
acetate, 10 mM Calcium Chloride (CaCl2), 15% Glycerol, pH 5.8). The suspension was 
incubated on ice for 45 minutes and was collected by centrifugation at 2,000 g for 10 
minutes at 4ºC. Finally, cells were resuspended in 8 ml of RF2 (10 mM 
Morpholinopropanesulfonic acid (MOPS), 10 mM RbCl, 75 mM CaCl2, 15% Glycerol), 
and were used immediately or were stored at -70 ºC. 
  
Yeast and E.coli transformation procedures 
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All yeast transformations were performed according to the standard lithium-treatment 
procedure (Ito et al., 1983; Kaiser et al., 1994). All E.coli transformations were prepared 
using chemically competent E. coli cells according to standard laboratory protocols 
(Sambrook et al., 2001).  
 
Standard yeast media and growth conditions 
 
Yeast cultures were grown at 30 °C. Standard yeast media and standard procedures for 
yeast cultivation, phenotypic and genetic analysis, transformation, sporulation and 
dissection were used (Kaiser et al., 1994). Sporulating cultures were dissected using a 
micromanipulator (Ergaval Series 10 from Carl Zeiss or the Singer MSM System 300). 
Cell counts were performed using a hemacytometer (Brightline). Synthetic media lacking 
adenine, leucine, or uracil are designated as –Ade, -Leu, and -Ura, respectively. In all 
cases when the carbon source is not specifically indicated, 2% glucose (Glu) was used. 
The synthetic medium containing 2% galactose (Gal) or 2% galactose and 2% raffinose 
(Gal+Raf) instead of glucose was used to induce the GAL promoter. 10 or 50 µM copper 
sulfate (CuSO4) was used to induce overproduction of proteins under control of the 
CUP1 promoter.  Liquid cultures were grown with at least  1/5 liquid/flask volumetric 
ratio in a shaking incubator (200-250 rpm). Yeast transformants were checked in all cases 
on YPG (medium containing glycerol as carbon source). Petites that are respiratory 
deficient do not grow on YPG or on medium containing galactose as the sole carbon 
source and were not considered for future use. 
 
Yeast DNA isolation 




Plasmid and genomic DNA from yeast cultures was colle ted according to standard 
laboratory protocols (Kaiser et al., 1994).  Briefly, cells from late log phase cultures were 
centrifuged at 7000 g, and cell pellets were resuspended in 500 µl of 1M Sorbitol, 0.1 M 
EDTA, pH 7.5 containing 4% of a 50 ug/ml lyticase solution and were incubated at 37° C 
for approximately 3 hours. Cells were briefly spun down at 12,000 x g, and pellets were 
resuspended in 500 µl of a 50 mM Tris-HCl (ph 7.4), 20 mM EDTA solution. SDS was 
added to a final concentration of 1%, and the samples were incubated at 65°C for 30 
minutes. 2 ml of 5 M potassium acetate was added and s mples were placed on ice for 1 
hour. Following 12,000 g centrifugation, 0.75 ml isopropanol was added to the 
supernatants and samples were centrifuged at 12,000 g for 5 minutes. Supernatants were 
discarded, and pellets were dried, resuspended in 0.4 ml TE (pH 7.4) plus 22 µl of a 1 
mg/ml solution of RNAse A, and incubated at 37°C for 30 minutes. DNA was 
precipitated with 2 volumes of 95% isopropanol. Samples were centrifuged at 12,000 g 
for 15 minutes, and pellets were washed with 70% ethanol. DNA pellets were dried and 
resuspended in 50 µl TE (pH 7.4).  
 
Protein isolation and analysis 
 
Yeast protein isolation and centrifugation analysis were conducted using standard yeast 
laboratory procedures (Kaiser et al., 1994; Sambrook et al., 2001). Yeast cultures were 
grown in liquid media selective for the protein expressing plasmid.  Cells were collected 
by centrifugation at 2,000 g for 5 minutes at 4 ºC, followed by washing cells with 300 µl
of ice-cold lysis buffer (25 mM Tris PH 7.5, 0.1M Nacl, 10mM EDTA, 100ug/ml 
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cycloheximide, 2mM benzamidine, 20ug/ml leupeptin, 4ug/ml pepstatin A, 1mM NEM, 
1X protease inhibitor cocktail form Roche Diagnostic  GmbH, 2mM PMSF)  Then the 
cells were resuspended in 2 volumes of ice-cold lysis buffer, and ~300 µl of acid washed 
glass beads were added. Cells were lysed by vortexing 6 times for 30seconds, with at 
least 1 minute on ice between vortexes. Cell debris wa  removed by centrifugation at 
2,000 g for 5 minutes. To conduct the centrifugation analysis, the isolated total cell lysate 
was fractionated by centrifugation at 16,000 g for 30 minute at 4 ºC. The supernatant was 
placed into a fresh tube, and the pellet was resuspended in an equal amount of the lysis 
buffer. SDS, glycerol, 2-mercaptoethanal and Tris-HCl (pH 6.8) were added to every 
sample to final concentrations of 2.5 %, 10 %, 5 % and 25 mM, respectively. Resulting 
samples were boiled for 10 minutes (or not boiled to keep the SDS-stable amyloid) to run 
on the standard SDS-polyacrylamide (SDS-PAGE) gel or st red at -70 ºC. Western blot 
was used to detect the protein signal. Protein gelsw re transferred onto Hybond ECL 
nitrocellulose membranes and reacted to the appropriate antibodies. 
 
In addition to Western blotting, the Dot blot was al o used to detect the protein signal. 
The Dot-blot apparatus was purchased from Bio-Rad. Cell lysate (50 µl, diluted if 
required) with 2%SDS was loaded onto the Immobilon-P PVDF membrane (activated in 
methanol before use) and waspre-equilibrated on the dot blot apparatus.  The membrane 
needed to be equilibrated with 3 washes of SDS wash buffer (10mM Tris Ph 8.0, 150mM 
NaCl, 01.% SDS) prior to loading the samples. Binding took place over 20 minutes, and 
the membrane was then washed twice with SDS wash buffer. Finally the membrane was 
removed and reacted to appropriate antibodies.  




Quantitative assay for [PSI+] de novo induction rate 
 
Plasmids bearing target proteins (e.g. chimeric N-PrP proteins) under CUP1 promoters 
were transformed into the [psi-pin-] strain GT409. Transformants were grown on media 
selective for the plasmid (e.g. –Ura) and tested on YPG media to rule out the respiratory 
deficient colonies. The pre-culture was grown in liquid selective media for up to 2 days 
until the OD600 reached 2.5. The numbers of cells were counted, an then used to 
inoculate liquid induction media (e.g. –Ura +10 µM CuSO4) to a concentration of 1X106 
cells/ml. The cells were then grown at 30°C with shaking. At the desired time points, 0, 
12, 24, 48 and 72 hours, aliquots of the cell culture were taken, washed with water, and 
cells were counted and plated on both selective media (e.g. –Ura, in order to check the 
cell viability rate) and selective media without adenine (e.g. –Ura-Ade, in order to check 
the [PSI+] de novo induction rate). The cell viability rate was obtained by dividing the 
viable colony number from selective medium bty the otal number of cells plated. The 
final de novo [PSI+] induction rate was obtained by dividing the Ade+ colony number 
from -Ura–Ade medium by the total number of cells plated, and then by dividing again 
by the cell viability rate. Approximately 500 cells were plated on selective media at each 
of the time points, and between 1X104 to 1X106 cells (depending on the induction ability 
of the protein) were plated on –Ura-Ade medium at each time points. To ensure accuracy, 
only plates containing fewer than 500 colonies were counted. The quantitative test was 
repeated 3 times for each construct.   
 
GFP detection by fluorescence microscopy 
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GFP fluorescence images were taken using live cultures. An aliquot of cells was placed 
onto a glass slide; it was sealed with a coverslip using nail polish. Images were scanned 
using an Olympus BX41 microscope with a 100X objectiv , with a narrow band GFP 
filter. Typically, Cultures were grown overnight in the inducer containing medium (e. g. 
–Ura with copper sulfate medium for genes expressed under CUP1 promoter). Only cells 
showing fluorescence were counted and grouped into different classes based on the 
patterns observed. The excitation wavelength was 543 nm for the helium-neon laser 
(rhodamine fluorescence), and 488 nm for the argon laser used to visualize GFP.   
 
Secondary Immunofluorescence straining  
 
A secondary immunofluorescence straining technique was used to visually detect the 
aggregation of certain proteins in living cells in cases when there was no fluorescence tag 
on the proteins. The cells were grown in media selectiv  for the protein expressing 
plasmid and contained the proper promoter-inducing agent (e.g. -Ura+100 µM CuSO4 for 
plasmid pMCUP1-N-PrP90-230). The cells were fixed by adding formaldehyde directly to 
the culture to a final concentration of 4% and cultures were incubated for 15 minutes at 
room temperature. To destroy the cell wall, cells were then gently spun down, washed 
twice in solution B, resuspended in 1 ml of the same solution. Cells were then treated by 
adding 2 µl of 2-mercaptoethanol and 20 µl of a 1mg/ml lyticase and were incubated for 
30 minutes at 37°C. Cells were precipitated again and washed twice with solution B. For 
immunofluorescence staining, fixed cells with destroyed cell walls were resuspended in 
100 µl of solution F (100 mM potassium phosphate buffer pH 7.4, 1 mg/ml BSA, 15 mM 
sodium azide, 15 mM NaCl) containing the appropriate ntibody (to detect N-PrP, an  
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Anti-PrP 6H4, 1:500 dilution was used), incubated in the dark for 1 hour, washed 10 
times with solution F, and resuspended in solution F containing the appropriate 
rhodamine-conjugated secondary antibodies (Alexa Fluor 488 goat anti-mouse, 1:500 
dilution). Refer to Table 2.3 for appropriate antibody concentration used in each case. 
After a one hour incubation in the dark, cells were washed 10 times with solution F and 
resuspended in phenylenediamine mounting solution (1 mg/ml p-phenylenediamine, 
Sigma, in 1X PBS and 90% glycerol) to prevent bleaching of the rhodamine conjugates 
(Pringle et al., 1991). Preparation for imaging was accomplished by placing an aliquot of 
cells onto a glass slide, and sealing the coverslip to the slide with clear nail polish. 
Samples were visualized under fluorescence microscope with a 488nm excitation 
wavelength. Only cells showing fluorescence were counted and analyzed. 
   
Cytoduction  
 
Cytoduction is the transfer of cytoplasm material from one strain of yeast to another, 
without transferring any nuclear genes (Conde et al., 1976). The recipient strain is 
respiratory-deficient and karyogamy-defective, and possesses a recessive mutation for 
cycloheximide resistance (cyhr).  Since the kar1-1 recipient strain is defective in nuclear 
fusion, and the nuclei segregate during mitosis by defective mating with the donor strain, 
only the cytoplasm material (e.g. mitochondria and prion amyloid) is transferred into the 
recipient strain. The respiratory-proficient cytoductants were selected on a synthetic 
medium containing 2% ethanol (instead of glucose). This counterselected against the 
respiratory-deficient recipient, and 5 mg/l cycloheximide, counterselected against donor 
cells and diploids (heterozygous by cyhr). (See figure 2-7, panels III-IV for the 
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cytoduction scheme). The experimental procedures is described in (Borchsenius et al., 
2006), with slight modification for this work. The donor strain was mated with the 
recipient strain GT953 on a YPD plate, was incubated at 30 oC for 12 hours, and the 
cytoductants were then obtained by velveteening to selective media as described above. 
The presence of [PSI+] in cytoductants was tested by monitoring the growth on selective 
media lacking adenine.      
 
2-3 Results 
2-3-1 Development of a yeast assay for prion induction by mammalian amyloidogenic 
protein 
 
The mammalian prion protein PrP tends to form a PrPSc-like conformation in yeast 
cytoplasm upon overproduction, presumably due to the less glycosylated and greater 
reducing environment (Ma and Lindquist, 1999). The yeast model can serve as a 
powerful system to study the initial steps of de novo PrPSc formation. However, there is 
no reliable phenotypic assay to monitor the formation of the PrPSc-like conformation in a 
yeast system. 
 
 In order to overcome this obstacle, we developed a de novo [PSI+] induction system to 
phenotypically monitor PrP aggregation in yeast. The PrP90-230 fragment, a region 
essential and sufficient for prion transmission (Peretz et al., 1997) was fused to the C-
terminal end of the Sup35 prion domain (N). (Figure 2-1) The chimeric N-PrP protein 
was shown to aggregate in the cytoplasm of mammalian cells and displayed increased 
resistance to proteinase K (Krammer et al., 2008). We proposed that overproduction of 
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N-PrP in yeast cells can induce the de novo formation of [PSI+] in the absence of other 
pre-existing yeast prions. This can ultimately serve as a phenotypic assay for PrPSc 
formation in a yeast model.    
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Figure 2-1. Construction of Sup35N-PrP chimeric protein. The Sup35N-PrP was 
constructed by fusing the PrP90-230 region to the C-terminal end of Sup35N.  
 
 
Sup35N-PrP induced de novo formation of [PSI+] in the absence of other prions  
 
In order to test the [PSI+] de novo induction ability of the chimeric protein N-PrP, the 
plasmid pMCUP1-N-PrP90-230 was transformed into the [psi
-pin-] strain GT409. Plasmids 
pMCUP1, pMCUP1-PrP90-230 and pMCUP1-SUP35N were also tested as controls. With 
transient overproduction (2 days on selective media –Ura with 10 µM CuSO4), nonsense 
suppression was detected in the strain containing N-PrP (Figure 2-2 A), indicating the 
formation of [PSI+].  The Ade+ colonies were cured by GuHCl, an agent eliminating all 
known yeast prions. In contrast, overproduction of Sup35N did not induce [PSI+] 
formation efficiently in [pin-] strain. Notably, overproduction of PrP itself did not induce 
[PSI+], indicating that the physical link with Sup35N is important. Without 
overproduction, N-PrP did not induce [PSI+] efficiently (data not shown), corresponding 
35                                                                                                                                                     
 
 
to the finding that PrP only aggregates in the yeast cytoplasm upon overproduction (Ma 
and Lindquist, 1999).  A quantitative test was performed in order to accurately check the 
[PSI+] induction rate of N-PrP (Figure 2-2 B). After transient overproduction (24 hours in 
–Ura medium with10 µM CuSO4), N-PrP induced [PSI
+] in a rate as high as 86 per 105 
cells, comparing with 2.6 per 105 cells from Sup35N and 0.6 per 105 cells from empty 
vector control. 
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Figure 2-2. Transient overproduction of Sup35N-PrP induced de novo formation of 
[PSI+] in the absence of other prions. “N-PrP”, “N”, “PrP”, and “vector” refer to 
Sup35N-PrP, Sup35N, PrP90-230 and empty vector respectively. Nonsense suppression of 
[PSI+] is checked on –Ade media. A- Transient overproduction of N-PrP in a [psi-pin-] 
strain induced de novo formation of [PSI+], while overproduction of PrP90-230, Sup35N or 
empty vector induced no or little [PSI+]. The Ade+ colonies induced by Sup35N-PrP was 
GuHCl curable. B- Quantitative test of the [PSI+] induction rate of Sup35N-PrP, Sup35N 
and empty vector in [psi-pin-] strain. The proteins were overprocued in liquid –Ura Meida 
containing 10 µM CuSO4 for 24 hours, numbers of de novo induced Ade
+ colonies were 
counted on –Ura-Ade plates. Each group was tested 3 times. Check the method section 
for detailed description. C- De novo [PSI+] induction by N-PrP can be visually monitored 
by Sup35NM-GFP (NM-GFP). After overproduction in liqu d –Ura meida containing 
100 µM CuSO4 for 24 hours, aggregation of NM-GFP was monitored by fluorescence 
microscopy. Cells with NM-GFP aggregates were counted and the aggregation rate was 
calculated. D- With transient overproduction, N-PrP-HA induced de novo [PSI+] 
formation while N-HA did not. E- Protein expression levels of N-PrP-HA and N-HA in 
[psi-PIN+] strain (cells were incubated in liquid –Ura meida containing 0 or 10 µM 
CuSO4 for 2 days) were checked with dot blot assay. HA antibody was used for the 
immunostaining. F- Protein expression levels of Sup35N-PrP and PrP90-230 in [psi-pin-] 
strain (cells were incubated in liquid –Ura meida containing 10 µM CuSO4 for 2 days) 
were checked by SDS-PAGE and western blot. Anti-PrP (4H11) was used for the 
immunostraing. G- The checked proteins were expressed under GAL promoter. By 
galactose-induced overproduction, N-PrP still induced de novo [PSI+] formation in [psi-
pin-] strain, while other proteins did not. H- Cured by Hsp104, the N-PrP induced [PSI+] 
strain was mated with PIN tester strain. No [PSI+] was induced in the diploid strain, 
indicating no [PIN+] existed. Known [PIN+] and [pin-] strains were tested as controls.  I- 
After loss of the N-PrP expressing plasmid from the de novo induced [PSI+] strain, the 
37                                                                                                                                                     
 
 
prion was stably maintained after 3 passages of growth n YPD, while GuHCl efficiently 
eliminated the prion state.  
 
 
[PSI+] formation can also be visually detected by monitoring the Sup35NM-GFP 
aggregates with a fluorescent microscope. To do this, pMCUP1-N-PrP90-230 
and pRS315/PCUP-Sup35NM-sGFP plasmids were co-transformed into the [psi
-pin-] 
strain GT409. The strain was inoculated into induction medium (liquid –Ura+100 µM 
CuSO4) which promotes the overproduction of N-PrP and NM-GFP, and the GFP signal 
was monitored using fluorescence microscopy. Sup35NM-GFP aggregated in [PSI+] cells 
(Paushkin et al., 1996) and formed dots or filamentous structures (Figure 2-2 C). When 
overproduced together with N-PrP, the frequency of cells with NM-GFP aggregates was 
5.1%, which was much higher than that of Sup35N or the empty vector. Notably, the 
NM-GFP aggregation rate was higher than the [PSI+] de novo induction rate, because 
only a portion of the cells having NM-GFP aggregation turned into [PSI+].   
  
N-PrP and Sup35N were tagged with HA for the purpose f assessing protein levels. It 
was shown that the HA tag does not affect the [PSI+] induction ability of N-PrP (Figure 
2- 2 D). In the yeast strain GT159, protein expression of N-PrP-HA and Sup35N-HA is 
of the same level, either with or without overproduction (Figure 2-2 E). In the yeast strain 
GT409, the protein expression level of N-PrP and PrP are comparable after 
overproduction (Figure 2-2 F).  
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Since we induced N-PrP overproduction with CUP1 promoter, it is possible that the [PSI+] 
inducibility is promoter-dependent or copper-dependant. To rule out this possibility, we 
constructed N-PrP, PrP and Sup35N plasmids under the galactose-inducible promoter 
GAL (pLA1-N-PrP90-230, pLA1-PrP90-230, pLA1-Sup35N). In the [psi
-pin-] strain GT409, 
after transient overproduction on galactose media, N-PrP induced [PSI+] de novo 
formation as well (Figure 2-2 G). Thus, the prion induction ability of N-PrP is directly 
associated with its overproduction, and it is not pr moter dependent.   
 
Overproduction of Sup35 or Sup35N can induce de novo [PSI+] formation facilitated by 
other yeast prions such as [PIN+] (Derkatch, et al., 1997). It is possible that the[PSI+] 
formation is due to the acquisition of [PIN+] or other yeast prions, but not to N-PrP 
overproduction. To rule out this possibility, we monit red the presence of [PIN+] in the 
de novo induced [PSI+] colonies. 6 individual [PSI+] colonies were cured by transient 
overproduction of Hsp104, without affecting [PIN+] in the cells. The existence of [PIN+] 
or other yeast prions was tested by mating cells with a [psi-pin-] strain that contained a 
Sup35 over-expressing plasmid. The diploid strain will have [PSI+] induced if [PIN+] or 
other yeast prions existed. The result (Figure 2-2 H) showed no [PIN+] or other yeast 
prions existing in the [PSI+] colonies, indicating overproduction of N-PrP induces de 
novo [PSI+] formation in the absence of other yeast prions.   
 
In order to check if N-PrP is required for propagation of the de novo induced [PSI+] prion, 
the N-PrP expressing plasmid was lost from the strain. After 3 passages of growth on rich 
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YPD medium, [PSI+] was still stably maintained in the strain (Figure 2-2 I). Thus, N-PrP 
was only required for [PSI+] de novo formation but not for [PSI+] propagation.   
 
2-3-2 Effects of PrP deletions on the [PSI+] induction ability of N-PrP   
We proposed that in the N-PrP chimeric protein, PrPspontaneously forms PrPSc-like 
structure and polymerized, which provides an initial nucleus. This facilitates prion 
formation of the Sup35N portion. Then the Sup35 protein is converted to the [PSI+] state 
via the prion isoform of Sup35N. Based on this hypothesis, elimination of the PrPSc 
forming ability of PrP will result in the failure of the [PSI+] induction by the chimeric 
protein N-PrP. To test this hypothesis, we constructed deletions in the PrP portion of the 
chimeric protein, and tested their [PSI+] induction abilities.    
    
It was shown that the N-terminal region of PrP (from residue 90 to 120) is critical for 
PrPSc formation (Muramoto et al., 1996; Peretz et al., 1997). Deletion of the PrP 
palindrome region (aa 112-119) prevents the formation of the PrPSc-like structure in the 
yeast cytoplasm (Norstrom et al., 2005). We deleted th  N-terminal residues 90-119 from 
PrP and constructed the N-PrP∆90-119 plasmid under the CUP1 promoter (pMCUP1-N-
PrP∆90-119). After transient overproduction in the [psi-pin-] strain GT409, no apparent 
[PSI+] induction by N-PrP∆90-119 was detected (Figure 2-3 A). A quantitative assay 
indicated that the [PSI+] induction rate of N-PrP∆90-119 was decreased dramatically 
when compared with that of N-PrP (Table 2-4). In the yeast strain GT409, the protein 
expression levels are similar for N-PrP and N-PrP∆90-119, either with or without 
overproduction (Figure 2-3 B). In these results, the [PSI+] induction ability of N-PrP was 
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lost when the prion formation ability of PrP region was eliminated. It strongly indicates 
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Figure 2-3. Effects of PrP deletions on the [PSI+] induction ability of Sup35N-PrP. 
The respective proteins were overproduced in -Ura media containing 10 µM CuSO4 for 2 
days. Nonsense suppression was tested on –Ade medium. A- After transient 
overproduction in [psi-pin-] strain, Sup35N-PrP∆90-119 did not induce [PSI+] formation, 
while Sup35N-PrP∆172-230 and Sup35N-PrP∆160-230 induced [PSI+] formation more 
efficiently than Sup35N-PrP. B-Protein expression levels of Sup35N-PrP and Sup35N-
PrP∆90-119 were checked by SDS-PAGE and western blot. Anti-PrP (4H11) was used 
for the immunostaining. C- Protein expression level of Sup35N-PrP, Sup35N-PrP∆172-
230 and Sup35N-PrP∆160-230 were checked by dot blot assay. Anti-PrP (6H4) was used 




Sup35N-PrP                                     8.6X10-4 7X10-5
Sup35N-PrPΔ90-119 4.4X10-5 1.3X10-5
Sup35N-PrPΔ160-230 7.5X10-2 4.96x10-3
Chimeric constructs               Ade+ frequency Standard deviation
Table 2-4. Frequencies of [PSI+] induced  by Sup35N-PrP and the deletions
 
(The proteins were overproduced in –Ura liquid media containing 10 µM CuSO4 for 24 
hours. Each group was tested 3 times; see the method section for detailed description) 




During prion conversion, the C-terminal region of PrPC is transformed from an α -helix 
rich structure into a β -sheet rich structure, and is included in the amyloid core (Cobb et 
al., 2008). In order to check how the C-terminal region affects PrPSc de novo formation, 
we constructed PrP C-terminal deletions in the chimeric protein N-PrP.   
 
We deleted the C-terminal residues of 160-230 or 172-230 from PrP and constructed the 
N-PrP∆160-230 and N-PrP∆172-230 plasmids under the CUP1 promoter (pMCUP1-N-
PrP∆160-230, pMCUP1-N-PrP∆172-230). Interestingly, after transient overproduction in 
GT409, the [PSI+] inductions by the C-terminal deletions were much stronger than that of 
the N-PrP wild type (Figure 2-3 A). Quantitative tests indicated that the [PSI+] induction 
rate of N-PrP∆160-230 was increased dramatically when compared to that of N-PrP 
(Table 2-4).  In the yeast strain GT409, the protein expression of N-PrP, N-PrP∆160-230 
and N-PrP∆172-230 were found to be similar after overproduction (Figure 2-3 C).   
 
Based on these results, we concluded that the PrP C-terminal region has an anti-prion 
formation effect, whereas, deletion of this region promotes PrPSc de novo formation. This 
result is supported by some clinical evidences for human GSS disease. As a prion disease 
caused by PrPSc formation, one case of inheritable GSS disease was associated with a 
nonsense mutation at residue 160 in human PrP (corresponding to residue 159 in mouse 
PrP).  Additionally, another human prion disease PrP-CAA (prion protein cerebral 
amyloid angiopathy) is associated with nonsense mutations at residues 145 or 163 in 
human PrP (corresponding to residues 144 and 162 respectively in mouse PrP). In all of 
these cases, the C-terminal truncated PrP promotes th  PrPSc associated diseases, 
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implicating the anti-prion formation effect of the C-terminal region. The effect of N-
PrP∆160-230 in this study is closely related to the nonsense mutations (160/stop or 
163/stop) occurring in certain prion diseases.  
 
2-3-3 Mammalian Aβ42 protein induced [PSI+] in the yeast assay   
 
Alzheimer's disease is a severe neurodegenerative disorder characterized by amyloid 
formation and accumulation of Aβ42 protein.  The mechanism of Aβ42 structural 
conversion and amyloid assembly is not yet clear. It was found that Aβ42 can aggregate 
spontaneously in the yeast cytoplasm. Here, we wanted to check Aβ42 with the [PSI+] de 
novo induction system in a yeast model.  
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Figure 2-4. Construction of Sup35N-Aβ and Sup35NM-Aβ chimeric proteins. The 
Sup35N-Aβ and Sup35NM-Aβ were constructed by fusing the Aβ1-42 region to the C-
terminal end of Sup35N or Sun35NM. Numbers correspond t  amino acid positions.  
 
 
We fused human Aβ42 to the C-terminal end of either Sup35N or Sup35NM to construct 
the chimeric proteins N-Aβ42 and NM-Aβ42 respectively (Figure 2-4). In order to test 
the [PSI+] de novo induction ability of the Aβ42 chimeric proteins, plasmids pMCUP1-N-
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Aβ42 and pMCUP1-NM-Aβ42 were transformed into the [psi-pin-] strain GT409. 
Plasmids pMCUP1, pMCUP1-SUP35N and pMCUP1-NM-HA were also tested as 
controls.  With transient overproduction (2 days on –Ura selective media with 10 µM 
CuSO4), nonsense suppression was detected in the strain containing N-Aβ42 and NM-
Aβ42 (Figure 2-5 A), indicating the formation of [PSI+].  The [PSI+] colonies induced by 
N-Aβ42 and NM-Aβ42 were also GuHCl curable (Figure 2-6 B). Notably, the [PSI+] 
induction ability of NM-Aβ42 was weaker than that of N-Aβ42, presumably because of 
the solubility promoting effect of the Sup35M region (Paushkin et al., 1996). Sup35M 
may inhibit the aggregation of Aβ42 in the chimeric protein NM-Aβ42 and then 
consequently, weaken its [PSI+] induction ability. The same effect was detected for the 
chimeric protein NM-PrP, which could barely promote any [PSI+] induction when 
compared to N-PrP (date not shown).   
 
As for N-PrP, N-Aβ42 and NM-Aβ42 are only needed for the [PSI+] de novo formation 
but are not required for [PSI+] propagation. After loss of the N-Aβ42 or NM-Aβ42 
plasmids from the de novo induced [PSI+] strain, the prion state was still maintained well 
(Figure 2-5 C, D).   
 
The de novo induced [PSI+] prion can be cured by transient overproduction of Hsp104, 
either with or without the N-Aβ42 or NM-Aβ42 plasmid in the strain.   
After Hsp104 curing, the strain harboring the N-Aβ42 plasmid had a low level of [PSI+] 
re-induction, promoted N-Aβ42 on a normal expression level.    
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Figure 2-5. Transient overproduction of Sup35N-Aβor Sup35NM-Aβ induced de 
novo formation of [PSI+] in the absence of other prions. The respective proteins were 
overproduced in -Ura media containing 10 µM CuSO4 for 2 days. Nonsense suppression 
was checked on –Ade media. GPD-HSP104 refers to Hsp104 over expressing plasmid 
which was lost from the cells after the overproduction process. NM-AβTM refers to NM-
Aβ with triple mutations. A-Transient overproduction of Sup35N-Aβ (N-Aβ) or 
Sup35NM-Aβ (NM-Aβ) in a [psi-pin-] strain induced de novo formation of [PSI+], while 
overproduction of Sup35N or Sup35NM did not induce [PSI+] formation. B- Protein 
expression levels of NM-Aβ42 and Sup35NM-HA (after overproduction) in [psi-pin-] 
strain were checked by SDS-PAGE and western blot. An i-Sup35N was used for the 
immunostraing. C-The Ade+ colonies induced by N-Aβ or NM-Aβ were GuHCl curable. 
D, E- The prion state was maintained after loss of N-Aβ or NM-Aβ plasmid from the 
strain. Transient overproduction of Hsp104 cured the [PSI+] strains with or with the 
plasmid. F-Transient overproduction of the NM-Aβ with triple mutations 
F19S/F20S/I31P did not induce de novo [PSI+] formation in [psi-pin-] strain.   
  
 
In order to prove that the aggregation of Aβ42 is required for the [PSI+] induction ability, 
we designed NM-Aβ42TM with triple mutations F19S/F20S/I31P in the Aβ42 portion. 
Substitutions of Phe19, Phe20, and Ile31 were previously shown to inhibit aggregation of 
Aβ42 in vitro and to prevent its neurotoxic effects (Hilbich et al., 1992; Morimoto et al., 
2004). It was inferred that Aβ42 aggregation is inhibited by the triple mutations i  the 
chimeric protein, and so its effect on the [PSI+] induction ability was then tested. The 
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result showed that after transient overproduction in the [psi-pin-] strain GT409, no [PSI+] 
was induced by NM-Aβ42TM (Figure 2-5 E). Inhibition of Aβ42 aggregation eliminated 
the [PSI+] induction ability of chimeric protein NM-Aβ42, which supports our hypothesis 
described above.  
  
2-3-4 Biochemical characterization of N-PrP in yeast  
When expressed in the mammalian cytoplasm, N-PrP proteins form aggregates 
spontaneously and can be precipitated down from cell lysate (Krammer et al., 2008). To 
test the N-PrP protein in yeast cells, we transformed pMCUP1-N-PrP90-230 into strains 
GT409 [psi-pin-], GT159 [psi-PIN+] and GT81-1C [PSI+PIN+], respectively. After 
transient overproduction in selective medium (-Ura+100 µM Cu) for 24 hours, the cells 
were fixed and checked by secondary immunofluorescence straining (see methods section 
for the detailed description). Visualized by staining, N-PrP formed dot-like aggregates in 
all 3 strain types having different prion backgrounds (Figure 2-6 A). In a [psi-pin-] strain, 
24% of cells contained N-PrP aggregates, the rest of which only showed fluorescent 
backgrounds. In [psi-PIN+] and [PSI+PIN+] strains, there were 33% and 34% of cells with 
N-PrP aggregates, respectively. Based on these results, we concluded that N-PrP tends to 
aggregate in the yeast cell after overproduction. However, the aggregation rate was not 
affected much by the prion background in the cell.  
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Figure 2-6. Characterization of Sup35N-PrP aggregate in yeast cells of various prion 
backgrounds. Anti-PrP (6H4) antibody was used for immunofluorescence staining and 
immunostaining (western blot). A-After transient overproduction, N-PrP expressed in 
[psi-pin-], [pin-PIN+] or [PSI+PIN+] strains were detected by secondary 
immunofluorescence staining. Aggregation structures (multiple dots) were detected in all 
cases, with respective frequencies listed in the figure. B- Cell lysates were extracted from 
the respective strains bearing N-PrP. Centrifuged at 16,000g for 30min in 4oC, the 
supernatants and pellets were collected, boiled, an then analyzed by SDS-PAGE 
followed with western blot. Most, if not all, of N-PrP is precipitated down from the cell 
lysates of [psi-pin-],[pin-PIN+] or [PSI+PIN+] strains. C-.Cell lysates with 2%SDS was 
loaded for SDS-PAGE, either with or without boiling. N-PrP did not enter the 
polyacrylamide gel without boiling from [PSI+PIN+] sample, while N-PrP entered the 
polyacrylamide gel with or without boiling from [psi-pin-] or [psi-PIN+] samples.    
 
 
We also performed a centrifugation analysis to testhe aggregation state of the N-PrP 
protein from [psi-pin-], [psi-PIN+] and [PSI+PIN+] strains (Figure 2-6 B). Cell lysates 
were extracted from the respective strains, followed by centrifugation at 16,000g for 30 
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minutes in 4oC. The supernatant and pellet were collected separately, boiled and analyzed 
by SDS-PAGE. The protein gel was analyzed by western blot with a PrP antibody (6H4). 
The result showed that most, if not all, of the N-PrP is precipitated down into the pellet in 
all three type of strains with different prion background.  Based on this result, all or most 
of N-PrP aggregates in yeast cells can then be precipitated down. However, only a 
portion of the aggregates are big enough to be detected by immunofluorescence straining.    
 
The amyloid structure formed by prions is very stable and detergent insoluble. In order to 
test if N-PrP forms a highly ordered amyloid structure, we performed the gel entry assay. 
2% SDS was added to cell lysate from [psi-pin-], [psi-PIN+] and [PSI+PIN+] strains. Then 
the samples were either boiled for 10 minutes or were not boiled and were then analyzed 
by SDS-PAGE. If N-PrP forms a SDS-insoluble amyloid, then it can not enter the 
polyacrylamide gel without boiling. The result showed that N-PrP from the [PSI+PIN+] 
cell lysate is SDS-insoluble and can not enter the polyacrylmide gel without boiling. N-
PrP from [psi-pin-] or [psi-PIN+] cell lysates was SDS-soluble and could enter the 
polyacrylamide without boiling (Figure 2-6 C).   
 
Based on the results above, we concluded that N-PrP aggregates spontaneously in yeast 
cells, independently of the presence of endogenous prions. However, a SDS-insoluble 
complex of N-PrP could only be detected in a [PSI+] strain. Although PrP can potentially 
form a prion like structure in yeast, this state may not be properly propagated. The 
propagation of yeast prions depends on the chaperone Hsp104 whose ortholog has not 
been identified in mammalian cells. The propagation of PrPSc may depend on a different 
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system which does not exist in the yeast cell.  Forthis reason, it is possible that PrP can 
not be assembled into the amyloid, or the assembled complex can only exist transiently. 
So, there is no SDS-insoluble complex of N-PrP detect d in the [psi-] strain.  In the [PSI+] 
strain, the Sup35N region of N-PrP is thought to be converted into the prion isoform and 
forms the amyloid core, which may, in turn, stabilize the PrPSc-like structure. N-PrP may 
be also associated into the Sup35 prion amyloid, via the Sup35N region. These explain 
the SDS-insoluble property of N-PrP from the [PSI+] strain.  
 
2-3-5 Propagation of [PSI+] state by N-PrP 
  
In order to test the propagation of the [PSI+] state by N-PrP alone, we designed a plasmid 
shuffle experiment and checked the maintenance of [PSI+] by cytoduction. We selected 
the [PSI+] strain GT1535, with a genomic SUP35 gene deletion and containing a Sup35 
expressing plasmid. Then we performed a plasmid shuffle to replace the original Sup35 
plasmid with the plasmids pMCUP1-N-PrP90-230 and pRS315-SUP35MC, which express 
N-PrP and Sup35MC respectively (Figure 2-7 A, panel I-III).  Without its prion domain, 
Sup35MC can not propagate [PSI+], however, it is needed for cell viability. Then, we 
performed cytoduction to check whether [PSI+] was maintained by N-PrP in the strain 
(Figure 2-7 A, panel III, IV).  Cytoduction is the transfer of cytoplasm from one strain of 
yeast to another, without transferring any nuclear genes (see methods section for detailed 
procedures). By cytoduction of the test strain with the [psi-] recipient strain GT953, the 
cytoplasm material (including the N-PrP complex) was tr nsferred to the recipient, which 
was obtained using cytoductant selective media. The pr sence of [PSI+] in the 
cytoductants was monitored on selective medium without adenine.  
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Figure 2-7. Cytoduction test for the [PSI+] maintenance by Sup35N-PrP. 
A- [Sup35],[MC] and [N-PrP] refer to plasmid expressing Sup35, Sup35MC or Sup35N-
PrP proteins respectively. Panel I-III: scheme of plasmid shuffle. Panel III-IV: scheme of 
cytoduction. sup35∆ [PSI+] strain GT1535 containing [Sup35] (stage I) was transformed 
with [N-PrP] and [MC] together (stage II), and then the original [Sup35] was lost from 
the strain (stage III). The strain containing [N-PrP] and [MC] was used as cytoduction 
donor whose cytoplasm was transferred to the sup35∆ [psi-] recipient strain containing 
[Sup35]. The [PSI+] state will be transfer to the cytoductant if it is maintained by N-PrP 
in the donor strain. As controls, Sup35N, PrP90-230, empty vector and full length Sup35 
were tested in the same way as N-PrP. B- The cytoductants from donor strains expressing 
the respective proteins (listed in the picture) were checked on the selective media without 
adenine. The existence of [PSI+] in the cytoductants was judged by the nonsense 
suppresion. In most cases, N-PrP maintained [PSI+] and converted Sup35 into [PSI+] state 
in the cytoductant. Sup35N or full length Sup35 propagated [PSI+] state with full 
efficiency, while PrP90-230 alone did not maintain [PSI
+].     
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The results showed that a majority of [psi-] recipients became [PSI+] (Figure 2-7 B) with 
a [PSI+] conversion rate of 82% (Table 2-5). This result indicates that N-PrP can maintain 
[PSI+] in the absence of full length Sup35, and it can co vert native Sup35 back into the 
[PSI+] state in the cytoductant strain. For controls, we tested [PSI+] propagation using 
either Sup35N, PrP90-230, full length SUP35 or an empty vector, in the same manner as for 
N-PrP. The following corresponding plasmids were usd:  pMCUP1-SUP35N, pMCUP1-
PrP90-230, pCUP-SUP35, and pMCUP1. The results showed that either Sup35N or full 
length Sup35 can propagate [PSI+] with full efficiency, while PrP90-230 alone can not 
maintain [PSI+] (Figure 2-7 B; Table 2-5).    
 
% of [PSI+] 
Cytoductants
Donor                     Recipient
Cytoductants
Total         [PSI+]
GT1535 [N-PrP]         GT953 ([psi-])            45             37                    82
GT1535 [N]                GT953 ([psi-])            48             46                    96
GT1535 [PrP]            GT953 ([psi-])            48              0                       0
GT1535 [vector]        GT953 ([psi-])             44              0                       0  
GT1535 [Sup35]        GT953 ([psi-])            25              25 100
Table 2-5. Cytoduction test for [PSI+] maintenance
 
 
The molecular chaperone Hsp104 is crucial for [PSI+] propagation; however, excess 
Hsp104 will eliminate [PSI+] from the yeast cell.  In order to check how Hsp104 affects 
the [PSI+] state maintained by N-PrP, plasmid pZTD104, a Hsp104 overproducing 
plasmid, was transformed into a strain bearing the prion state of N-PrP. After transient 
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overproduction of Hsp104, pZTD104 was then lost from the strain. The prion state of N-
PrP was then checked with cytoduction again with the [psi-] recipient strain GT953 
(Table 2-6). Based on this result, the prion state of N-PrP was lost in 15 colonies out of 
the16 individual colonies checked, for a prion state loss at a rate of 94%. In contrast, for 
the strain without Hsp104 overproduction, the prion state of N-PrP was lost at a rate of 
25%. Although not 100% efficient, transient overproduction of Hsp104 did cure the [PSI+] 
state maintained by N-PrP at a high rate.  
 
% of [psi-] 
Cytoductants
Donor                                  Recipient
Cytoductants
Total         [psi-]
GT1535 [N-PrP]                     GT953 ([psi-])                   8               2                        25%             
GT1535 [N-PrP] Hsp104        GT953 ([psi-])                  16             15                        94%
GT1535 [Sup35]                    GT953 ([psi-])                   6               0                          0
GT1535 [Sup35] Hsp104        GT953 ([psi-])                  8               8                         100%                        
GT1535 [N]                             GT953 ([psi-])                  8               0                           0
GT1535 [N] Hsp104                GT953 ([psi-])                  8               0                           0  
Table 2-6. Cytoduction test for the prion curing effect of excess Hsp104 
 
 
For the control, the [PSI+] state maintained by either Sup35N or full length Sup35 was 
also tested in the same manner. The results showed that [PSI+] can be stably maintained 
by Sup35 or Sup35N at a normal Hsp104 expression level; however, overproduction of 
Hsp104 can fully cure the Sup35 maintained prion but can not cure the Sup35N 
maintained prion (Table 2-6). Some recent studies indicated that Sup35 M region can 
affect [PSI+] propagation, presumably by mediating the interaction between Hsp104 and 
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Sup35 prion aggregate (Liu et al., 2002; Chen et al., 2007). Without a proper binding site 
in the Sup35N prion, it is likely that overproduced Hsp104 can not efficiently interact 
with the Sup35N prion and eliminate it. Thus, the PrP region may facilitate an interaction 
between Hsp104 and the prion state of N-PrP, which accounts for its high curing rate by 
excess Hsp104.   
  
2-3-6 Prion-like state of N-PrP facilitates the [PSI+] de novo formation 
Since excess Hsp104 can cure [PSI+] without affecting other prions, we wanted to 
eliminate the [PSI+] prion induced by N-PrP by transient Hsp104 overproduction, and 
then check whether the PrPSc-like state remained to facilitate [PSI+] de novo induction 
again. To check this, we randomly picked 30 individual [PSI+] colonies induced by N-
PrP overproduction (described in section 2-3-1). In order to eliminate the [PSI+] prion, 
the Hsp104 overproducing plasmid pZTD104 was transformed into the strain and was 
then lost from the strain. With transient overproduction of Hsp104, [PSI+] was eliminated 
in all colonies, as shown by the nonsense suppression assay. Then pLA1-SUP35, a 
plasmid expressing the Sup35 protein under the GAL promoter, was transformed into 
these colonies. By transient overproduction of Sup35 rotein on galactose medium, the de 
novo formation of [PSI+] was monitored by nonsense suppression. The results howed 
that one colony out of 30 had de novo [PSI+] formation, and it was labeled as a N-PrP 
reinducible strain (Figure 2-8 A).  
 
53                                                                                                                                                     
 
 






N-PrP:  - +   
N-PrP reinducible




Boil:        +            - +              -




N-PrP:     -/+       +
N-PrP reinducible
 
Figure 2-8. Prion-like state of N-PrP facilitated the de novo [PSI+] formation. 
Nonsense suppression was checked on –Ade medium.  A- The [PSI+] prion induced by 
N-PrP was cured with excess Hsp104, then Sup35 was overproduced in the strain and de 
novo formation of [PSI+] was monitored by nonsense suppression. Of all the 30 
individual colonies checked, one colony had de novo [PSI+] formation after Hsp104 
curing (named as N-PrP reinducible). No [PSI+] was induced if Sup35 was produced on a 
normal level. As controls, empty vector or N-PrP plasmid was transformed into [psi-pin-] 
strain. With overproduction of Sup35, no [PSI+] was induced in the control strains. B- N-
PrP reinducible strain was treated with GuHCl, and then no [PSI+] could be induced 
again after Sup35 overproduction. C- N-PrP expressing plasmid was lost from the N-PrP 
reinducible strain, then no [PSI+] could be induced again by Sup35 overproduction. Then 
the N-PrP expressing plasmid was transformed back to the strain ( N-PrP -/+) (D), no 
[PSI+] was induced after Sup35 overproduction. E- N-PrP from reinducible strain or [psi-
pin-] strain was tested by gel entry assay. Cell lysate wi h 2%SDS (boiled or not boiled) 
was loaded for SDS-PAGE and then checked by western blot with Anti-PrP (6H4). N-PrP 
from the reinducible strain is SDS-insoluble and can not enter polyacrylamide gel without 
boiling. In contrast, N-PrP from [psi-pin-] strain is SDS-soluble and can enter 
polyacrylamide gel without boiling.  
 
 
Notably, after treating the reinducible strain with GuHCl, [PSI+] could not be induced 
again by Sup35 overproduction (Figure 2-8 B). Since GuHCl is a prion eliminating agent, 
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there should be some prion or prion-like complex responsible for the de novo [PSI+] 
induction in the reinducible strain. We further tested the reinducible strain by eliminating 
the N-PrP expressing plasmid from it, and then, no [PSI+] could be induced again by 
Sup35 overproduction (Figure 2-8 C). This result indicated that no [PIN+] or other yeast 
prions existed in the reinducible strain; and N-PrP p otein is required for the [PSI+] re-
induction. Next, the N-PrP expressing plasmid was tr nsformed back into the reinducible 
strain, but [PSI+] still could not be induced by Sup35 overproduction (Figure 2-8 D). 
Based on these results, we concluded that the prion-like complex formed by N-PrP is 
GuHCl curable and is responsible for the de novo [PSI+] re-induction; without the prion-
like structure, N-PrP can not facilitate [PSI+] induction.          
 
Finally, we biochemically tested the N-PrP protein by the gel entry assay (Figure 2-8 E). 
The cell lysate was extracted from an N-PrP reinducible strain, 2%SDS was added and 
the samples (either boiled for 10 minutes or not boiled) were analyzed using SDS-PAGE. 
The result showed that N-PrP was SDS-insoluble; it could not enter tha polyacrylamide 
gel without boiling. In contrast, N-PrP extracted from a [psi-pin-] strain was soluble and 
did enter into the polyacrylamide gel without boiling. This result further supports the 
hypothesis that N-PrP forms a prion-like complex in a reinducible strain.  
 
2-3-7 The effects of PrP and Aβ on the [PSI+] associated cell toxicity  
  
 
Although the presence of the [PSI+] prion by itself is not detrimental to yeast cells, 
overproduction of SUP35 or Sup35NM in [PSI+] cells leads to growth inhibition 
(Dagkesamanskaya et al., 1991; Derkatch et al., 1996). The source of this lethality has 
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been attributed to either the accumulation of Sup35p isoforms that might be toxic to the 
cell, or the depletion of essential factors (Derkatch et al., 1996; Derkatch et al., 1998).  
 
In order to check how PrP or Aβ chimeric proteins affect the [PSI+] associated cell 
toxicity, the respective proteins were overproduced in a [PSI+] strain and the cells 
viabilities were monitored (Figure 2-9).   
 
To test the PrP chimeric proteins, plasmids pMCUP1-SUP35N, pMCUP1-N-PrP90-230, 
pMCUP1-N-PrP∆90-119, pMCUP1-N-PrP∆160-230, and pMCUP1-N-PrP∆172-230 
were transformed into the [PSI+PIN+] strain GT81-1C. Beginning from a uniform cell 
density (106 cells/ml), strains with different plasmids were incubated in overproduction 
inducing media (-Ura+100 µM CuSO4, liquid). After eith r 0 hour or 48 hours of 
incubation, cell viabilities were monitored by serial dilutions of the cell cultures followed 
by spotting onto selective media (-Ura).   
 
Without protein overproduction, the [PSI+] strain grew at the same level with no cell 
toxicity effect. However, after protein overproduction, the [PSI+] strain with Sup35N 
showed a severe growth defect. Interestingly, N-PrP or N-PrP∆90-119 ameliorated the 
cell toxicity; PrP∆90-119 almost restored the cell viability to its normal level, as 
compared to the strain harboring an empty vector. In contrast, strains with N-PrP∆160-
230 or N-PrP∆172-230 exhibited cell toxicities of the same level as that of Sup35N.  
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Figure 2-9. The effects of PrP and Aβ on the [PSI+] associated cell toxicity. “vector” 
refers to empty vector expressing no proteins in the cell. With or without incubating in 
the overproduction-inducing media (-Ura+100 µM CuSO4), [PSI+] cell cultures bearing 
the respective proteins were serial diluted and spotted onto synthetic media selective for 
the plasmids (-Ura). The [PSI+] associated toxicity was monitored by the growth on the 
synthetic media.  
 
 
More evidence supported the hypothesis that [PSI+] associated cell toxicity is attributed 
to the depletion of certain essential factors. Specifically, overproduction of Sup35 in a 
[PSI+] strain was shown to sequester Sup45 (eRF1), another translation termination factor 
which is required for cell viability. Overproduction of Sup35NM in a [PSI+] strain was 
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shown to sequester Sup35, and the depletion of functional Sup35 caused cell death 
(Vishveshwara et al., 2009).  
 
For this result, overproduction of Sup35N in a [PSI+] strain was presumed to sequester 
functional Sup35 (Sup45 may be sequestered too) and c use cell death. Notably, N-
PrP∆90-119, which induced no de novo [PSI+] formation, had the least cell toxicity effect; 
N-PrP which moderately induced [PSI+] formation, had a slight cell toxicity effect; N-
PrP∆160-230 or N-PrP∆172-230, which promoted a much stronger [PSI+] induction, had 
severe cell toxicity. Since the formation of a PrPSc-like structure is attributed to the de 
novo [PSI+] induction, the cell toxicity effect may also be linked to the conformation of 
the PrP region in the chimeric proteins. Based on this result, native structured PrP∆90-
119 may prevent Sup35N from interacting and sequestering Sup35. Following the 
formation of a PrPSc-like structure, Sup35N more easily sequesters Sup35, causing cell 
death. Also, the PrPSc-like structure may have toxic effect, in of itself.           
.   
The Aβ42 chimeric proteins were also tested in the same manner. Plasmids pMCUP1-N-
Aβ42, pMCUP1-NM-Aβ42, pMCUP1-NM-HA, pMCUP1-SUP35N and pMCUP1 were 
transformed into the [PSI+PIN+] strain GT81-1C. After overproduction, N-Aβ42 
moderately ameliorated the cell toxicity effect as compared to the toxic effect caused by 
Sup35N.   The cell toxicities caused by excess NM-Aβ42 and NM-HA were of a similar 
level, and they both caused a severe growth defect. The fusion of Aβ42 may prevent 
Sup35N from interacting with and sequestering functio al Sup35, which would decrease 
the cell toxicity to some extent. It is reported that aggregation of Aβ42 has neurotoxic 
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effects in a mammalian model (LaFerla et al., 2005; Hardy et al., 2002). The aggregation 
of Aβ42 in the chimeric proteins may also be partially responsible for the cell toxicity.  
  
2-4 Discussion:  
 
We have developed a novel yeast model system which employs the de novo prion 
induction assay for studying properties of a mammalian prion protein.  
Overproduction of Sup35 or Sup35N can promote de novo [PSI+] formation only in the 
presence of other yeast prions such as [PIN+]. In our system, by fusing Sup35N with 
mouse PrP90-230, the overproduced chimeric protein can promote de novo formation of 
[PSI+] even in the absence of other pre-existing prions.  Previous studies showed that 
mammalian PrP can aggregate and form a PrPSc-like conformation in yeast cells, while 
the N-terminal region is required for PrPSc formation both in mammalian cells and yeast.  
Notably, our result showed that a deletion of N-terminal residues 90-119 from PrP 
eliminates the [PSI+] induction ability of N-PrP, indicating that the prion-like state 
formed by PrP was important for the [PSI+] induction ability of N-PrP.  Interestingly, 
deletions of PrP C-terminal residues 160-230 or 172-230 promote the [PSI+] de novo 
induction by N-PrP. Clinical evidence showed that several cases of human prion diseases 
were linked with nonsense mutations in the C –terminal region of the PrP coding gene.  
Especially, one case of human GSS disease was linked with a nonsense mutation at 
residue 160 in PrP, which agreed with our result.   
When overexpressed in [psi-pin-], [psi-PIN+] or [PSI+PIN+] strains, N-PrP can always be 
precipitated from yeast extracts at 16,000 g, indicating that it is aggregated. 
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Immunofluorescence analysis detected multiple N-PrP aggregates (similar to those 
formed by yeast prions) in a significant fraction of the yeast cells. This is in agreement 
with both our prion induction results and previous observations by I. Vorberg (Krammer 
et al., 2008), who detected multiple N-PrP aggregates in mammalian cells. Therefore, 
patterns of N-PrP aggregation are conserved between yeast and mammals.   
 
Detergent resistance is a common feature shared by prion amyloids. With overproduction, 
the SDS-insoluble complex of N-PrP can be detected in the [PSI+] strain but not in the 
[psi-] strain. The amyloid-like structure formed by PrP (part of N-PrP) may be unstable 
and could be stabilized by the Sup35N (part of N-PrP) prion amyloid in a [PSI+] strain.  
In an exceptional case, from a [PSI+] colony induced by N-PrP, a detergent-insoluble N-
PrP complex was identified after eliminating the [PSI+] prion by excess Hsp104. The 
prion-like structure of N-PrP (without overproduction in the strain) was shown to 
facilitate the [PSI+] de novo formation upon Sup35 overproduction.       
 
We further investigated [PSI+] propagation by N-PrP. It was shown that N-PrP can
maintain the [PSI+] sate even in the absence of full length Sup35, and the [PSI+] state can 
be transfered back to native Sup35. The Sup35N region from N-PrP is expected to 
maintain the [PSI+] conformation by itself, and by interacting with te N domain of 
native Sup35, it converts Sup35 into the prion state. Notably, Hsp104 overproduction can 
not cure the [PSI+] state maintained by Sup35N. However, excess Hsp104 cures [PSI+] 
maintained by N-PrP quite efficiently.        
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Based on the evidence above, we propose a model for the PrP induced [PSI+] de novo 
formation (Figure 2-10). With overproduction of N-PrP, the chimeric proteins aggregate 
together via PrP regions. Then, a transient prion-like structure is formed by PrP, which 
increases the initial nucleation of the attached Sup35N and promotes its prion formation. 
The resulting prion would incorporate full-length Sup35 and convert it into a prion state. 
Therefore, the initial PrPSc-like formation would be fixed in the form of a stably inherited 
phenotype, detectable by the nonsense suppression assay.  
 












Figure 2-10. Model for PrP mediated [PSI+] induction. PrP is shown in dark filling 
and Sup35N is in blank filling. Circles and squares correspond to non-prion and prion 
isoforms, respectively. Oval corresponds to Sup35MC region.   
  
 
Interestingly, a physical link between Sup35N and PrP is important for the prion 
induction, as overproduction of PrP alone does not promote [PSI
+] induction. In contrast, 
the [PIN+] prion promotes [PSI+] de novo formation without any physical linkage 
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between Rnq1 and Sup35.  The seeding model suggests that the [PIN+] prion promote 
[PSI+] formation by providing a nucleus to facilitate the initial prion formation (Derkatch 
et al., 2001). Yeast prions always contain Q/N-rich prion domains; one yeast prion may 
nucleate other yeast prion via heterologous prion dmains. However, mammalian PrP is 
nonhomologous to any of the yeast prion proteins, ad it does not have a Gln/Asn-rich 
prion domain. So presumably, the cross-seeding between mammalian PrP and a yeast 
prion can not occur spontaneously unless a physical link existed. Data showed that  [PSI+] 
can also promote [PIN+] formation, while  another yeast prion [URE3] can promote both 
[PIN+] and [PSI+] formation (Derkatch et al., 2000; Derkatch et al., 2001). Moreover, it 
was also shown that mixing of the PrP prion with Aβ42 amyloid in an Alzheimer’s 
transgenic mouse model dramatically accelerated both pathologies (Morales et al., 2010).  
Heterozygous prions cross-seeding may be a widespread phenomenon which needs to be 
further studied.   
 
The de novo prion induction assay can also be employed to study other mammalian 
amyloidogenic proteins which cause diseases. Fused with Sup35N or Sup35NM, Aβ42 
also induced [PSI+] de novo formation in the absence of other yeast prions. Inhibiting the 
aggregation of Aβ42 by triple mutations eliminated the [PSI+] induction ability of NM-
Aβ42. Other amyloid related properties of Aβ42 are ready to be studied in this model, 
which may shed light on the mechanism of Alzheimer’s disease.   
 
Yeast cytoplasm is an environment that is very different from one where PrPSc or Aβ 
usually exist. However, these differences are more likely to influence prion propagation 
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rather than initial prion formation targeted in our work. Aggregation and prion formation 
by PrP are detected even in vitro (Castilla et al., 2005; Kocisko et al., 2006), and yeast 
prions can be formed in bacterial (Garrity et al., 2010) or mammalian (Krammer et al., 
2009) cells. Thus, major parameters of the initial prion formation are largely independent 
of the environment.  
 
The initial origin of the prion conformation is largely unclear. Prion diseases occur more 
sporadically, and some heritable prion diseases are linked with disease-promoting 
mutations in PrP (van der Kamp et al., 2009; Solomon et al., 2009). Systematic studies of 
mutations preventing PrP from forming a prion have be n difficult due to both laborious 
monitoring techniques in animal models and the multi-step nature of the prion disease, 
itself, making it hard to determine which step is influenced by a mutation. In most cases, 
it was impossible to conclude whether these mutations affect prion formation or only 
propagation of the pre-existing prion state. Directly linked with the initial prion formation 
of PrP, our assay provides a unique opportunity for the simple and very fast large-scale 
screening of the effects of PrP mutations, as well as chemicals and peptides on prion-
inducing properties of PrP.  This may help to develop new anti-prion and prophylactic 
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2-5 Conclusions:  
 
 
• Fusion to PrP or Aβ42 enabled the sup35 prion domain to induce de novo 
formation of [PSI+] in the absence of other prions. 
 
• PrP deletions strongly affected the [PSI+] inducing ability of N-PrP.   
 
• Sup35N-PrP aggregated in the yeast cells and acquired the SDS-insoluble state 
only in the presence of the Sup35 prion. 
 
• The prion state can be maintained by N-PrP in the absence of full-length Sup35, 
partially cured by excess of the Hsp104 chaperone. 
 
• The prion-like state of Sup35N-PrP facilitated the [PSI+] de novo induction in the 
absence of other prions.  
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CHAPTER 3  







Prion is a widespread phenomenon  
All proven yeast prions contain a Q/N-rich prion domain (PrD) which is essential for 
prion formation and propagation. 1-4% of eukaryotic proteins contain a QN-rich domain 
similar to known yeast PrDs based on amino acid composition (Harrison and Gerstein, 
2003). A genome-wide screening in S. cerevisiae yeast was conducted to search for prion 
candidates (Alberti et al, 2009). About 100 proteins were identified having a PrD-like 
sequence, and 19 of them can potentially form a prion-like structure. One protein (Mot3) 
was confirmed to form a prion with a phenotype that is likely to be advantageous under 
certain environmental conditions. The prion-forming ability may be widespread among 
yeast proteins or proteins from other species. Moreover, non-QN rich prion proteins are 
found in other organisms, e.g. Het-s in the fungus Podospora (Malato et al., 2007) and 
PrP in mammals. Thus, the prion phenomenon may be wid spread in many species, and 
there are many more prion-forming proteins yet to be identified and studied.    
.  
Biological roles of yeast and fungal prions 
Prion formation of the mammalian prion protein is strongly linked to a series of 
neurodegenerative diseases in humans and animals. However, yeast prions generally do 
not appear to bestow detrimental effects on the cells, and the prions may even convey 
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protective functions in some adverse environments.  For example, yeast cells having the 
[SWI+] prion were shown to be resistant to the microtubule disruptor, benomyl. Another 
yeast prion [MOT3+] was shown to increase cellular resistance to certain cell wall 
stressors. The [OCT+] prion induces flocculation, a growth form that has been shown to 
protect cells from various stresses (Du et al., 2008; Patel et al., 2009). The [PSI+] prion is 
only detected in laboratory strains; however, it was shown that the prion-forming ability 
of the Sup35 prion domain is maintained throughout yeast evolution despite divergence 
of the specific amino acids (aa) sequences (Chen et al, 2007, Chernoff et al, 2000). In fact, 
it was shown that the Sup35 prion provides resistance to some toxic agents or 
unfavorable conditions in certain laboratory strains (True and Lindquist, 2000). It was, 
thus, proposed that a decrease in the translation termination function of Sup35 increases 
phenotypic variability by allowing readthrough of stop codons, thus producing proteins of 
extended lengths. 
 
Methods of prion detection 
Prion is a widespread phenomenon in yeast; however, ou  understanding of the 
distribution and biological roles of yeast prions in natural conditions remains at 
rudimentary levels, partially due to the lack of sequ nce- and phenotype-independent 
approaches for prion detection and monitoring. Approaches to phenotypic detection of 
yeast prions are based on functions of individual prion proteins (Chernoff et al, 2002). 
Prion formation usually causes a partial loss of the protein’s normal function, such as for 
the Sup35 prion [PSI+] or for the Ure2 prion [URE3]. Specially designed strains are 
needed to detect the phenotypes caused by each respective prion. Thus, phenotypic 
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detection is restricted to a specific prion in each case. Alternatively, candidate prion 
domains can be tested in phenotypic assays by fusing them to the proteins with known 
function, e.g. Sup35MC. However, not all fusions remain functional and, therefore, not 
all prion domains can be detected in this way. 
 
Biochemical approaches for prion detection in vivo are based on the properties of 
amyloid aggregates, such as protease resistance and high sedimentation rate (Chernoff et 
al, 2002). However, these approaches can only be applied to detect prions formed by 
known proteins, since a specific antibody or tag is needed to visualize the target protein. 
None of these approaches is selective enough for separating a previously unknown prion 
from the cell lysate, as many non-prion proteins or protein complexes are also 
characterized by high proteinase resistance or high sedimentation rate. Amyloids 
assembled in vitro can be detected by electron or atomic force microscopy, a thioflavin T 
(ThT) or Congo Red binging test, a detergent insolubility test or a light-scattering test 
(for review see Chernoff et al, 2002). These techniques work well for detecting purified 
proteins; however, they are not easily applicable to living cells or cell extracts. It was 
reported that [PIN+] containing structures have been stained and visualized by ThT 
(Douglas et al, 2008); however, the specificity and sensitivity of this staining remains 
questionable. Amyloid fibers have been detected in [URE3] cells with electron 
microscopy, but only when Ure2 is overproduced at a high level (Speransky et al, 2001).   
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The “gel-entry” assay can efficiently identify prions formed by known proteins 
(Kushnirov et al., 2006). Yeast prions or other amyloids of different fiber types are 
detergent-insoluble; they cannot enter polyacrylamide gel without boiling. So by 
comparing boiled and unboiled samples of the same protein, prion-forming proteins can 
be distinguished from non-prion proteins.  The gel-entry assay cannot identify unknown 
prions, and it would be too laborious to use this method for a large-scale analysis. SDD-
AGE (semi-denaturing detergent-agarose gel electrophoresis) is also used to analyze 
prion polymers (Kryndushkin et al, 2003). Different sized prion polymers in 2% SDS can 
be separated by electrophoresis in a semi-denaturing agarose gel. This technique has been 
used extensively for confirming prion properties ofindividual proteins and for 
characterizing polymer size in vivo. However, this approach is not useful for prion 
screening, and it cannot identify unknown prions.  To date, no effective biochemical tool 
exists that can identify previously unknown prions i  cell extracts based solely on their 
physical patterns.  
 
The ability to form transmissible amyloids (prions) i  widespread among yeast proteins 
and is likely an intrinsic property of proteins from other organisms. However, the 
distribution of yeast prions in natural conditions is not yet clear, thus preventing us from 
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The main goal in this work is to develop and optimize the sequence-independent 
biochemical approaches for known and unknown prion detection in yeast. Large scale 
prion-profilling can be perfomed with the new approches, which can shed light on the 
relationship between prions and their adaptation to various environmental conditions in 
the yeast model.  
 
3-2 Materials and methods 
 
Yeast strains 
See appendix for a description of yeast strains used in this study. 
 
Gel preparation 
10% acrylamide gel:  2.64 ml DI water, 3.33 ml 30% Acrylamide, 1.33 ml 2% Bis, 2.5 ml 
1.5 M Tris PH 8.8, 0.1 ml 10% SDS, 0.1 ml 10% APS, 4 µl TEMD (for 10 ml gel) 
 
5% acrylamide gel (Stacking gel): 2.475 ml DI water, 0.833 ml 30% Acrylamide, 0.332 
ml 2% Bis, 1.26 ml 0.5 M Tris PH 6.8, 0.05 ml 10% SDS, 0.05 ml 10% APS, 7 µl TEMD 
( for 5 ml gel) 
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Flamingo staining was performed using a Flamingo Fluorescent Gel Stain kit from Bio-
rad, which provided a 0.5 ng sensitivity for protein v sualization. The gel was fixed for 2 
hours in fixing solution (40% (v/v) ethanol and 10% (v/v) acetic acid), and then strained 
in 1X Flamingo fluorescent gel stain solution for at least 3 hours. The gel was then 
washed with water and scanned using a Typhoon gel and blot imager from GE. Protein 





3-3-1 Adjustment of the “Gel-boiling” assay for prion profiling 
 
Amyloids formed by prions are detergent insoluble and cannot enter into polyacrylamide 
gel without boiling (Figure 3-1). This feature is ued to distinguish prion amyloids from 
other cellular proteins or from non-prion aggregates. 
 









Can not enter polyacrylamide gel





Can enter polyacrylamide gel  
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Figure 3-1. Yeast prion polymers are SDS stable.  SDS can disrupt the prion aggregate 
into stable polymers; the polymers are too big to enter polyacrylamide gel. Boiling of the 
prion polymers can destruct them into soluble monomers which can enter the 
polyacrylamide gel. In contrast, SDS can dissolve non-prion aggregate into soluble 
monomers which can enter the polyarylamide gel withou  boiling.        
 
The “gel-boiling” assay for prion detection (Kushnirov et al., 2006), modified by us and 
based on this principle, was used to detect and analyze amyloid-based prions in yeast 
strains. This experiment was performed using a standard SDS–PAGE; however, the gel 
uniformly consisted of a 10% acrylamide gel without the addition of a stacking gel. The 
cell lysate was extracted using a standard protocol, mixed with 4X sample buffer (0.25M 
Tris–HCl, pH 6.8, 8% w/v SDS, 8% 2-mercaptoethanol, 20% glycerol, 0.2% w/v 
bromophenol blue), incubated for 5 min at room temprature, and then loaded on a SDS-
PAGE gel without boiling. Only soluble proteins could enter the gel, while prion 
polymers remained trapped in the bottom of the wells. After the gel was run for a period 
of time, depending on the size of the target protein (for Sup35 it takes 45 ~ 60min until 
the bromophenol blue reaches the middle of the gel), electrophoresis was interrupted, and 
a new portion of polyacrylamide was added to the wells and allowed to solidify. This was 
followed by boiling the whole gel (gel was sealed in a plastic bag and submerged 
vertically in boiling water) for 10 min, cooling itdown and running it again. Due to the 
destruction of polymers by boiling, prion proteins previously trapped in the wells could 
now enter the gel in the second run. Western blot, followed by reaction with the 
appropriate antibody, allowed detection of the prion soform which was visible as the 
upper band. The non-prion isoform (that entered the gel without boiling) was visualized 
as the bottom band. The “gel-boiling” assay reproducibly distinguished prion isoforms of 
Sup35 and Rnq1 from the cell extracts (Figure 3-2 A, B). When compared to the “gel-
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entry” assay (cell extracts with 2% SDS were loaded for SDS-PAGE, with or without 
boiling; prion protein was identified through its ability to enter the gel), the “gel- boiling” 
assay distinguished prion isoforms from a single sample, and it also showed the 
proportion of protein found in the polymeric and the monomeric fraction. For the [URE3] 
prion amyloid, although boiling in 2% SDS was not sufficient to disaggregate the prion, 
boiling in a 8M urea solution could disaggregate it into monomers, and the Ure2 protein 
was found to enter the SDS-PAGE gel (Data not shown).   
 








Figure 3-2. “Gel boiling” assay identifies the prion forms of Sup35 and Rnq1 
proteins. Sup35 and Rnq1 anti-bodies were used to detect [PSI+] or [PIN+] respectively. 
The upper protein bands came from denatured amyloids, while the bottom bands came 
from protein monomers.  A,B- In [psi-] or [pin-] strains, Sup35 and Rnq1 are in monomer 
forms with 2%SDS, and can enter polyacrylamide gel without boiling. In [PSI+] or [PIN+] 
strains, Sup35 and Rnq1 are in amyloid form with 2%SDS, which can only enter 
polyacrylamide gel after boiling, appearing on the op of the gel. C- One example of 
prion profiling result. [PIN+] prion was identified from S. cerevisiae strain S288c. After 
GuHCl curing, there was only SDS-soluble Rnq1 protein d tected in the strain.     
  
 
3-3-2 Prion detection in yeast strains of various origins. 
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Previous screens for yeast prions have been performed for some randomly chosen strains 
with uncertain evolutionary relationships (Chernoff et al., 2000; Nakayashiki et al., 2005). 
Using the “gel-boiling” assay, we searched for prions within certain S. cerevisiae and S. 
paradoxus strains of known origin, having completely sequenced genomes and well-
defined phylogenetic relationships. These were provided by Drs. G. Liti and E. Louis 
(Liti et al., 2009). We have also checked 11 other S. cerevisiae strains having partially 
known phylogenetic relationships, provided by J. Fay (Fay and Benavides, 2005). In 
addition, we have checked two representative strains of the Petershoff Genetic Lines 
(PGL), the S. cerevisiae laboratory strain collection of St. Petersburg University, Russia, 
that is independent from the US laboratory strains, one commercial S. cerevisiae strain 
purchased from Mr. Beer, and Saccharomyces strains of different species used in our 
previous papers (Chernoff et al., 2000; Chen et al., 2007). (See appendix for the 
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Figure 3-3. Prion distribution among the yeast strains of various origins. 
Phylogenetic relationships of yeast strains are based on ref. Liti et al. 2009 and 
presented in a simplified way. “Wine” strains include grape, berry, sake and palm 
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wine strains. Sake group is mostly of Asian origin but also includes some palm 
wine strains from African sources.  
 
Although the [PSI+] prion is frequently found in laboratory strains originating from 
S288C or PGL strains, no prion form of Sup35 or Ure2 proteins are detected in 
Saccharomyces strains checked in this study. The “Gel-boiling” ass y detected the 
[PIN+] prion in 4 out of 36 natural and industrial strains of S. cerevisiae received from 
the Liti lab (Figure 3-2 C), as well as in two PGL laboratory strains and in the 
commercial strain obtained from Mr. Beer. In each strain containing [PIN+], after 
treatmentwith the prion-eliminating agent GuHCl, Rnq1 was present in the 
monomeric form within the strain. No [PIN+] prion was detected in the remainder of 
the S. cerevisiae strains or in any strains from species other than S. cerevisiae (Figure 
3-3).  
 
Our results agreed with previous data obtained by other groups, and we also found 
that all [PIN+]-containing strains originate from either laboratoy, brewery or bakery 
strains, while none of the 21 wine strains tested (including grape, palm and sake wine) 
or 13 wild strains tested contain the [PIN+] prion. The 3 [PIN+]-containing bakery 
strains are closely related to each other, while S288C that originates from rotting figs 
is diverged both from them and from other major distinct phylogenetic branches. 
Among non-sequenced strains, the [PIN+]-containing PGL laboratory strains are 
known to originate from bakery strains. Notably, byanalyzing previous prion 
screening data (Nakayashiki et al, 2005), it was also found that all [PIN+]-containing 
isolates having known origins originated from either the lab, brewery, bakery or clinic, 
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but never from the winery or from the wild. Taken together, these results suggest that 
the [PIN+] prion is underrepresented among the wine strains which are involved in an 
intense fermentation process resulting in accumulation of high concentrations of 
ethanol.  
 
3-3-3 Development of the “Agarose trapping” assay for prion profiling. 
In order to indentify unknown prions from a yeast strain, it is necessary to   isolate 
potential amyloids in the amount sufficient for visual or mass-spectroscopic detection. 
For this purpose, we developed an “agarose trapping” assay (Figure 3-4) that is based on 
the observation that detergent-insoluble prion polymers cannot enter into polyacrylamide 
gel but can move into the agarose gel (Kryndushkin et al., 2003).  
 
The experiment was performed on a SDS–PAGE base; however, a combined gel was 
used having a 1.8% agarose gel on the top and a 10% polyacrylamide gel on the bottom. 
Cell extracts were then mixed with 4X sample buffer (with 2% SDS in the final mixture) 
and were incubated for 30 min at room temperature. Samples were then loaded on the 
combined gel without boiling. With electrophoresis, the soluble proteins ran into the 
polyacrylamide gel, while the SDS-insoluble prion polymers were trapped on the bottom 
of the agarose gel. The electrophoresis was run for an extended length of time (3 hours or 
more) to make sure that all soluble proteins were run out of the agarose gel. The bottom 
portion of the agarose gel was cut out, boiled and then loaded onto a normal SDS-PAGE 
gel (for the purpose of loading, we used a low melting point agarose). After separation by 
electrophoresis, the trapped proteins were visualized by western blotting (in the case of 
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known prions) and by Flamingo staining (Berkelman et al., 2009) for any proteins present 
in sufficient amounts. For unknown prion identificat on, protein trapped in agarose were 




Protein with SDS 
boiled
















Figure 3-4. A model of the agarose trapping assay for prion identification.  Without 
boiling, prion polymers are SDS stable and can be trapped in agarose. The trapped 
polymers can be either extracted and analyzed by mass-spectroscopy or denatured by 
boiling and run on a SDS-PAGE gel to visualize individual proteins. If a sample is pre-
boiled, polymers are solubilized and cannot be trapped in agarose.  
 
  
Our results showed that the prion isoforms of Sup35, Rnq1 and Ure2 can be trapped in 
the agarose from their respective prion-containing cell extracts. The trapped proteins 
were visualized by western blot with respective antibodies (Figure 3-5 A-C).  In contrast, 
there were no prion proteins trapped from the pre-boiled samples of prion-containing 
extracts or from non-prion containing extracts. As an additional control, the non-prion 
protein Ade2 was tested and not found to be trapped in the agarose (Figure 3-5 D).   
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Figure 3-5. Identification of prion proteins by the agarose trapping assay  An 
analysis was performed as shown in Fig. 3-4. The prion forms of the proteins Sup35 (A), 
Rnq1 (B) and Ure2 (C) were detected by immunostaining with respective antibodies in 
the agarose traps of the respective prion-containing strains. However, they were not 
detected in the traps of non-prion strains or in cases when samples were boiled before 
trapping. (D) Ade2 protein, used as a control, was present in the total lysate but was not 
trapped in agarose for samples that were either boiled r not boiled.  
 
 
The protein samples from the agarose trap were also analyzed by MS, performed by E. 
Dammer and J. Peng (Emory University). Initially there were significant amounts of 
unspecific proteins detected in the samples, including high molecular weight (MW) 
complexes (e. g. ribosomes) and chaperons (e. g. Hsp70). To minimize contamination, we 
subjected the samples to additional treatments before loading. Cell extracts with 10%SDS 
were incubated at a higher temperature (370C) to removes most of the aggregate-
associated chaperones. Then the samples were centrifuged at high speed (200,000g, 
30mins) to remove most of the ribosomes and other complexes. This kept most of the 
prion polymers in solution. After these steps, the samples were run through the agarose 
trap, and the trapped proteins were analyzed by MS again. It was found that Sup35 
wasthe most abundant protein, and Rnq1 was the second m st abundant protein from the 
cell extract containing both proteins in the prion soforms ([PSI+ PIN+]). In the [psi- PIN+] 
sample, it was found that Rnq1 was the most abundant protein, while in the [psi- pin-] 
sample, none of these proteins was detected (Table 3-1). Ultimately, the “agarose 
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trapping” assay can potentially identify any prion-like complex that can move into the 
agarose gel but cannot enter into the polyacrylamide gel. 
 
Table 3-1. Proteins that are overabundant in the agarose traps of prion-containg strains
Protein Description Size, Abundance in the agarose traps 
(kD) [PSI+ PIN+]       [psi- PIN+] [psi- pin-]
Sup35 Prion (translation termination factor)      79 Highest None None
Rnq1 Prion (unknown function) 43 2nd highest High None
Pyk1 Pyruvate kinase 55 High Moderate Low
Tdh1/2/3 Trioso-phosphate dehydrogenase 37 High Moderate Moderate
Eno1/2 Enolase 47 Moderate         Moderate None
 
 
In addition to Sup35 or Rnq1, several more proteins were identified by MS which are 
exclusively or preferably abundant in [PSI+ PIN+] or in [psi- PIN+] extracts, when 
compared with non-prion extracts. Interestingly, all of these proteins turned out to be 
yeast glycolytic enzymes, including pyruvate kinase (Pyk1), triose-phosphate 
dehydrogenase (Tdh1, 2 and 3), and enolase (Eno1 and 2). The appearance of these 
glycolytic enzymes in the agarose trap does not appe r to be accidental. Previous results 
showed that Eno2 interacted with the Sup35 prion domain (Bailleul et al., 1999); Tdh and 
Eno2 were found to co-immunoprecipate with polyQ aggre ates produced in the prion-
containing strain (Wang et al., 2007). These results point to the possibility that prion 
formation may influence glycolysis, which represents one of the major driving forces of 
yeast adaptation and evolution.  
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Several more proteins were identified in agarose traps from both prion-containing and 
non-prion-containing cell extracts (Table 3-2). These include:  (1) High MW (200 kD or 
higher) proteins, including the glycoprotein Ygp1; (2) membrane-associated proteins 
Pma1/2; (3) the cell wall protein Bgl2; (4) actin which is the major component of 
polymeric cytoskeletal structuresand (5) and ubiquit n (Ub) which is attached to many 
misfolded or aggregated proteins and can form long poly-Ub chains. Some ribosomal 
proteins and ribosome-associated translational factors (Ef-1α or EF-2) were also detected 
in the agarose traps with variable abundance. All of these proteins were significantly less 
abundant than known prions. The contaminations do not prevent identification of proteins 
having the prion isoform.  Prion polymers can be removed from the sample by pre-
boiling, and prion containing strains can simply be cured by GuHCl; these enable us to 
distinguish prion proteins from the contaminants. Interestingly, Bgl2 is shown to possess 
amyloid properties (Kalebina et al., 2008), while Pma1 is suspected to be involved in a 
prion-like phenomenon related to glucosamine resistance (Brown and Lindquist, 2009), 
indicating that the presence of these proteins in our samples could not be due to simple 
contamination.   
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Table 3-2 . Background and contaminant proteins detected in agarose traps
Protein Description Size, kD
Mdn1 Midasin, involved in ribosome assembly and export 559
Gcn1 Positive regulator of Gcn2 kinase 297
Acc1 Acetyl-CoA-carboxylase, involved in fatty acid biosynthesis 250
Fas2 Fatty acid synthetase 207
Ygp1 Cell wall glycoprotein 37 (>200 when glycosylated)
Pma1/2 Plasma membrane ATPase 100/102
Act1 Actin, major component of cytoskeleton 42
Bgl2 β-glucanase,  cell wall protein with known amyloid properties 34
Some translation factors Associated with ribosomes 50-93
Some ribosomal proteins Components of ribosomes 15-25




3-3-4 Detection of new prion candidates with the “agarose trapping” assay 
We employed the “agarose trapping” assay to identify ew prion candidates within the 
set of yeast strains tested in section 3-3-2.  The agarose trapped samples were analyzed 
by loading and running on a SDS-PAGE gel, followed by Flamingo staining. The protein 
bands shown in the gel were cut out, extracted and sent for MS analysis. With this 
procedure, Sup35 and/or Rnq1 proteins were confirmed corresponding to the respective 
protein bands from [PSI+ PIN+] or from [psi- PIN+] samples (Figure 3-6). By analyzing 
several strains of various origins (Liti et al., 2009), Rnq1 was confirmed in the agarose 
trap from the extract of the bakery strain YS2 that w s previously shown to contain the 
[PIN+] prion.  In addition, several more bands were detect d in the extract of this strain 
(Figure 3-8), and at least some of them (as well as Rnq1) disappeared if samples were 
pre-boiled before agarose trapping (data not shown). O e of the bands corresponding to 
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55kD in size (also seen in laboratory [PSI+ PIN+] strain) was confirmed to be Pyk1 by 
MS analysis. As a pyruvate kinase functioning in the glycolysis process, Pyk1 was 
isolated in prion-containing strains by agarose trapping, indicating its amyloid-like 
character. Our results suggest that Pyk1 can potentially form a prion-like structure in a 
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Figure 3-6. Detection of new prion aggregates by agrose trapping. 1, 2 and 3 – 
isogenic lab strains ([PSI+ PIN+], [psi- PIN+] and [psi- pin-], respectively); 4 and 5 – 
natural strains, 6 – bakery strain YS2.  
 
3-4 Discussion  
In this work, we modified the “gel-boiling” assay and employed it to screen known 
prions in a set of yeast strains of various origins. To indentify unknown prions, we 
developed the “agarose trapping” assay. Some prion candidates were identified by this 
assay.  
 
With the “gel-boiling” assay, some known yeast prions were screened in a set of S. 
cerevisiae and S. paradoxus strains having known origins, completely sequenced 
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genomes and well-defined phylogenetic relationships (Liti et al., 2009).  Combined with 
our results and previous data, it was shown that the prion forms of Sup35 or Ure2 were 
not found in any of the natural and industrial strains. The [PIN+] prion was found in 
laboratory, brewery or bakery strains of S. cerevisiae, but not in wild or winemaking 
strains. [PIN+]-containing isolates originated from different sources and were mixed in 
the past with different phylogenetically separated branches (Figure 3-3); thus, it is clear 
that not all prion-containing strains have a common origin. It is possible that strains of 
different origins acquire different prions that are not compatible with each other. 
Alternatively but not exclusively, certain environmental conditions or genetic changes 
may influence the de novo formation and/or maintenance of certain prions.  
 
With the “agarose -trapping” assay, Sup35 and/or Rnq1 proteins were identified in their 
respective prion-containing strains. Additionally, several glycolytic enzymes were 
identified which are more abundant in prion-containing extracts when compared with 
non-prion extracts. Visualized by flamingo staining, a 55kD protein band was present in 
the [PSI+] and/or [PIN+] containing samples; MS results confirmed the protein o be the 
pyruvate kinase Pyk1. A mammalian homolog of pyruvate kinase was shown to form 
aggregates in vitro upon denaturing. It was noted that the aggregates were not completely 
solubilized after the denaturing agent was removed (Pierce and Stevens, 1983).  It was 
also found that a dysfunction of glucose metabolism was associated with Alzheimer's 
disease, featuring amyloid formation of Aβ42 (Hunt et al., 2007). Thus, Pyk1 may 
potentially form an amyloid-like structure that is promoted by other prions such as [PSI+] 
or [PIN+]. Alternatively, the glycolytic enzymes (including Pyk1) trapped from prion-
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containing cell extracts may not be prion, per se. They may interact tightly with prion or 
be included in the prion amyloid. Those proteins will st ll be of great interest, since they 
may help us to understand the biological effect of the prions. The specific presence of the 
glycolytic enzymes in the agarose traps from prion-c taining strains may point to the 
role of prions in modulating the parameters of glyco tic and respiratory pathways.  
 
A comprehensive prion profiling for known and unknown prions will help our 
understanding of the biological and evolutional role f prions.  Our established assays 
were proven to detect prions effectively and can be employed for the task of large-scale 
prion profiling. For profiling known prions, the “gel boiling” assay will be more 
applicable.  By using a larger gel with more wells, more samples can be analyzed in the 
same amount of time. For further high-throughput analysis, a specially designed device 
can be constructed usingthe same principle employed for  gel boiling. This device 
contains multiple holes (e.g. 96 holes), and each hole is filled with 10% polyacrylamide 
gel. By loading cell extracts with 2%SDS into each hole and performing electrophoresis, 
the non-prion protein will run out of the gel, while the prion polymers are trapped on the 
top. Then, the electrophoresis is interrupted, polyacr lamide is added to each hole and 
allowed to solidify, and the whole plate is then boiled. After a short electrophoresis run, 
the denatured prion polymers enter the gel and will be transferred to a nitrocellulose filter 
by western blotting and are reacted to the appropriate antibody. To screen unknown 
prions on a large scale, the “agarose-trapping” assay could be simplified to decrease the 
work amount. To do this, the samples are loaded on the agarose trap, and electrophoresis 
is run for an extended duration. After the first run, all of the non-prion proteins enter the 
83                                                                                                                                                     
 
 
polyacrylamide gel and eventually run out of it. The agarose gel containing trapped prion 
polymers is not cut out and is further tested in a new SDS-PAGE. The whole gel is boiled, 
cooled down, and electrophoresis is run again, followed by flamingo staining. The prion 
polymers are denatured with boiling and will enter polyarylamide gel, and the prion 
proteins will be visualized with flamingo staining.    
 
In summary, we developed and optimized new unbiased biochemical approaches for 
prion detection in yeast, which are potentially amenable to high-throughput analysis for 
large scale prion profiling. The prion detection approaches are applicable to other 
organisms such as humans or animals, which will provide easy detection tools for PrPSc 




• The “Gel-boiling” assay can effectively identify previously known prions from 
yeast strains of various origins.   
 
• The [PSI+] or [URE3] prions are not present in the 86 yeast strains of various 
origins, while the [PIN+] prion is underrepresented among the wine strains 
involved in an intense fermentation processes. 
 
•  The newly developed “Agarose-trapping” assay can identify known prions as 
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CHAPTER 4  








In contrast to all other known infectious agents, a prion is an infectious agent composed 
of protein in a misfolded form.  Apart from the nuclei  acid element, prion itself acts as a 
heritable protein-based element which shows non-Mendelian patterns of inheritance 
during meiosis. By studying yeast prions, three unus al genetic traits were proposed to 
distinguish prion from other nucleic acid-based replicons (Wickner et al., 1994). (1) The 
first is reversible curability. If a prion is cured, it should still be possible to arise again 
because the responsible protein is still produced in the cells. In contrast, curing of other 
nucleic acid-based replicons is irreversible unless they are re-introduced into the cell 
again. (2) Secondly, overproducing the prion protein increases the frequency of the prion 
formation. Since protein is the only agent responsible for prion formation, excess protein 
will increase the chance of prion formation. In contrast, overproducing a chromosomal 
protein is not likely to promote the formation of other nucleic acid-based replicons. (3) 
Lastly, a mutant phenotype may resemble the prion phenotype. If prion formation causes 
an inactivation of the normal form of the protein (such as for Sup35 or Ure2 prions), then 
the prion phenotype should be the same or similar to that produced by a mutation in the 
coding gene of the protein. This is the opposite of the relationship between nucleic acid-
based replicons and the corresponding genes.  
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Different from the classical yeast prions described fore, we found a new prion-like 
state called [MCS+] which exists only in yeast strains expressing Sup35 without the 
Sup35 prion domain. [MCS+] caused a nonsense suppression phenotype which was cured 
by the prion eliminating agent, GuHCl. However, theprion-like [MCS+] state followed a 
Mendelian pattern inheritance, suggesting the involvement of a nuclear element.  
 
Objectives 
The main goal of this work is to study the new prion like state [MCS+], which will help us 
understand the prion-related phenomena, as well as non ense suppression epigenetic 
control.  
  
4-2 Materials and methods:  
 




Plasmids used in this study are listed in table 4-1 












SourcePromoter Yeast markerProteinPlasmid name





The yeast strains used in this study are listed in table 4-2. 
MATα sup35Δ::nat, [CUP1-SUP35 URA3], can1Δ::STE2pr-
Sp_his5 lypΔ; his3Δ1 leu2Δ0 ura3Δ0 met1 5Δ0LYS2+GT1293
MATα sup35Δ::natR  can1Δ::STE2pr-Sp_his5 lypΔ his3Δ
leu2Δ ura3Δ met15Δ LYS2+ [SUP35MC URA3]GT1292
MATα can1D::STE2pr-Sp_his5 lypD; his3D1 leu2D0 ura3D0 
met1 5D0LYS2+OT372
MATa ade1-14 his3Δ leu2-3,112 trp1-289 ura3 kar1 cyhR rho-
sup35::HIS3 [SUP35C LEU2][psi-PIN+]GT1124
MATa ade1-14 his3Δ leu2-3,112 trp1-289 ura3 kar1 cyhR rho-
sup35::HIS3  [SUP35MC LEU2][psi-PIN+]GT1123
MATa ade1-14 his3Δ (or 11,15) lys2 ura3-52, leu2-3, 112 trp1
sup35::HIS3  hsp104::LEU2 [URA3, SUP35MC] GT1120
MATa ade1-14 his3Δ (or 11,15) lys2 ura3-52 leu2-3,112 trp1 
sup35::HIS3 [CEN LEU2 SUP35] [psi-pin-] GT671




Table 4-2: Yeast strains used in this study
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GT1120 was constructed by disrupting the genomic HSP104 gene in a [MCS+] bearing 
strain. A 4 kb DNA fragment was amplified by PCR from plasmid pYS-L5, containing 
the LEU2 gene marker with a flanking sequence homologous to the HSP104 gene. The 
primers used for the PCR were: GCCGCGATTTTTTTGTTCA and 
GCACCATCCTTTACAAT. By transforming the PCR-amplified fragment into a [MCS+] 
bearing strain, it replaced the 1kb HSP104 gene portion by homologous recombination, 
thus disrupting the genomic HSP104 gene in the strain. The resulting cells were grown n 




Yeast extract transfection  
  
 
To transfect [MCS+] cell extract into an isogenic strain bearing no [MCS+] factor, we used 
the transfection protocol described in Tanaka et al., 2004, with some modifications. Yeast 
strains to be transfected were grown in 50ml YPD media to an optical density of 0.5 at 
600 nm and were successively washed with sterile water nd 1M sorbitol, and 
resuspended in 20ml SCE buffer (1M sorbitol, 10mM EDTA, 10mM dithiothreitol, 
100mM citrate, pH 5.8). Cells were spheroplasted with lyticase (250 mg) and DTT 
(200µM) in SCE buffer at 30 oC for 30 min. Spheroplasts were washed with 1M sorbit l 
and STC buffer (1M sorbitol, 10mM CaCl2, 10mM Tris, pH 7.5). Pelleted cells were 
resuspended in 2ml STC buffer, and 100µl of the proto last suspension was mixed with 
up to 10µl of [MCS+] cell extract, 2 µg of the LEU2-based plasmid (pRS315)  and 10µg 
of salmon sperm DNA (100 mg/ml). Fusion was induced by the addition of 9 volumes of 
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PEG buffer (40% (w/v) PEG 4000, 10mM CaCl2, 10mM Tris, pH 7.5) for 30min. Cells 
were centrifuged, resuspended in SOS buffer (1M sorbitol, 7mM CaCl2, 0.25% yeast 
extract, 0.5% bacto-peptone), incubated at 30oC for 30 min and plated on synthetic media 
lacking leucine (selective for cells absorbing the transfection-mix) and were overlaid with 
top agar (2.5% agar). To check the transfection result, the transfectants were picked up, 






The synthetic genetic array (SGA) analysis (Tong et al., 2001) was performed in Dr 
Boone’s lab at the University of Toronto. The starting strain GT1292 was constructed by 
us and was based on the OT372 strain from Dr Boone’s lab.  Plasmid pmCUP1MCSc 
was transformed into the OT372 strain first. Then, the whole SUP35 gene in the genome 
of the host strain was replaced by a natNT cassette wi h a PCR-mediated gene deletion 
method (Tong et al., 2006). This starting strain cotained all of the genetic and antibiotic 
markers for a SGA screening and only expressed Sup35 without the prion domain. 
Another starting strain, GT1293, was constructed as a control. Plasmid pmCUP1MCSc 
from GT1292 was replaced with plasmid pCUP-SUP35. The resulting strain expressed 
only full-length Sup35. A small scale SGA screening was manually performed by us 
following the SGA protocol described in Tong et al., 2006. 
 
4-3 Results  
 
4-3-1 A [MCS+] prion-like state was identified in the yeast strain l cking the Sup35 prion 
domain 





Initially, a yeast strain expressing only the Sup35 rotein without the prion domain was 
constructed by a plasmid shuffle procedure (Figure 4-1 A). A Sup35MC-expressing 
plasmid (pmCUP1MCSc, with the URA3 marker) was transformed into the [psi- pin-] 
strain GT671 with the genomic SUP35 gene deleted, bearing a Sup35-expressing plasmid 
(pASB2, with the LEU2 marker). Then, the original Sup35-expressing plasmid was lost 
from the strain by counterselecting on –Ura and –Leu media.   Next, 20 individual 
colonies bearing only the Sup35MC plasmid were checked on –Ade media for nonsense 
suppression. Interestingly, after these colonies were patched on a –Ade plate and were 
incubated for more than 10 days, some Ade+ papillae appeared on one exceptional patch 
(Figure 4-1 A). The de novo-formed Ade+ papillae were individually picked and were 
treated with the prion eliminating agent GuHCl (5mM). Strikingly, one of the Ade+ 
colonies was cured, indicating a prion-like factor involved in it. The GuHCl-curable 
nonsense suppression state was named [MCS+].  This nonsense-suppression state was 
found to be stably maintained.  After 3 passages of gr wth on YPD, all of the daughter 
cells were still Ade+ and showed a white color on YPD (Figure 4-1 B).      
 
 





Figure 4-1. A prion like 
phenomenon [MCS+] is detected 
in a yeast strain lacking the 
Sup35 prion domain.   
A- The plasmid shuffle procedure 
is shown in the scheme. A [psi- 
pin-] sup35 strain with the 
SUP35 gene on a CEN plasmid 
was transformed with a CEN 
plasmid expressing Sup35MC. 
Then, the original Sup35-
expressing plasmid was lost from 
the strain, and only the SUP35MC plasmid was left. A er the plasmid shuffle, one 
exceptional colony showed nonsense suppression. Colony purification of the Ade+ 
papillae and one isolate was shown to be GuHCl-curable. The GuHCl-curable nonsense 
suppression state was termed [MCS+]. B-The [MCS+] colony was white in color on YPD 
media and turned a red color when the nonsense suppression state was eliminated by 
GuHCl. The [MCS+] state was stably propagated.   
 
 
4-3-2 Suppression in a [MCS+] strain is not due to prion formation by Sup35MC 
 
Since prion formation of Sup35 is known to cause nonsense suppression, one explanation 
for [MCS+] was due to prion formation by Sup35MC, even without the prion domain. To 
check this, a centrifugation analysis was performed. Cell extracts of the [MCS+] strain 
and the GuHCl-cured strain (named [mcs-]) were centrifuged at 8,000 g for 30 minutes at 
sup35 ∆ 
[SUP35] 
Transformation Lose a plasmid 









One exceptional  
colony 




[MCS+], 3 passages 
on YPD 
 GuHCl Cured 
(Curing rate: 72%) 
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4 oC. Then, the supernatant and pellet were collected, boiled and checked by SDS-PAGE 
and western blot. The distribution of Sup35MC protein in the supernatant and pellet was 
the same from the [MCS+] strain and from the [mcs-] strains (Figure 4-2). In contrast, 
most Sup35 was precipitated to the pellet from the [PSI+] strain, while most of the Sup35 
was retained in the supernatant for the [psi-] strain. Thus, Sup35MC did not aggregate in 
the [MCS+] strain, so the nonsense suppression was not due to prion formation of 
Sup35MC. 
     
                         
 
Figure 4-2. Centrifugation analysis of Sup35MC from [MCS+] strain. The speed of 
centrifugation was 8,000 g. “S” and “P” refer to supernatant and pellet, respectively.  The 
Sup35 antibody was used for the immunostaining detection.  
  
 
4-3-3 Different regions of Sup35 affect the appearance of the [MCS+] phenotype  
 
 
Since [MCS+] was found in the strain expressing only the Sup35MC protein but never in 
strains expressing full-length Sup35, the Sup35N domain may inhibit the existence of 
[MCS+]. Alternatively, [MCS+] has the same phenotype as [PSI+], so it may be ignored in 
normal strains producing full-length Sup35. In this case, the existence of [MCS+] may be 
irrelevant to the Sup35 protein.  
 
First, to eliminate the possibility that the [MCS+] phenomenon is plasmid-specific, we 
performed a plasmid shuffle to replace the Sup35MC-expressing plasmid 
   [PSI+]       [psi-]     [MCS+]    [mcs-]     
     S     P    S     P    S     P     S     P     
Sup35 
Sup35MC 
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(pmCUP1MCSc) with a different plasmid bearing SUP35MC (pRS315-SUP35MC). The 
result showed that the [MCS+] phenotype was not changed with a different plasmid 
(Figure 4-3).   
 
To test if [MCS+] can co-exist with Sup35C alone, plasmid pRS315-SUP35 del3ATG 
(expressing Sup35C) was transformed into a [MCS+] strain, and the Sup35MC plasmid 
was then lost. The result showed that nonsense suppression was not altered in the strain 
expressing only Sup35C (Figure 4-3), suggesting little or no effect of the Sup35M region 
on [MCS+].  
.  
In order to check if Sup35N affects the existence of [MCS+], plasmid pASB2 (expressing 
the Sup35 full length protein) was transformed into the [MCS+] strain, and the Sup35MC 
plasmid was then lost. With the existence of the Sup35 protein, the nonsense suppression 
phenotype of [MCS+] disappeared. Then a reverese shuffle was performed by 
transforming in the Sup35MC plasmid followed by loss of the full-length Sup35-
producing plasmid. The nonsense suppression was partially restored in the strain 
expressing only the Sup35MC again (Figure 4-3). Taken together, [MCS+] did not cause 
nonsense suppression in the presence of Sup35N; however, the propagation of [MCS+] 
was partially maintained, and the nonsense suppression could be restored when Sup35N 
was eliminated from the cell.       
 
 





Figure 4-3. Manifestation of [MCS+] is affected by different regions of Sup35. [MC], 
[C] and [SUP35] refer to CEN plasmids expressing Sup35MC, Sup35C or full-length 
Sup35 protein, respectively. [MC*] refers to a heterogeneic plasmid of [MC] which also 
expresses Sup35MC. Nonsense suppression was checked on –Ade media. A [MCS+] 
strain with [MC] (Stage I) was transformed individually with [MC*], [ SUP35] or [C] 
containing LEU2 markers (Stage II), and nonsense suppression was judged by the growth 
on –Ade media selective for both plasmids. After elimination of the original [MC] 
plasmid (stage III), there was only Sup35MC, full length Sup35 or Sup35C protein 
expressed in the strain respectively. Judged by the growth on –Ade media, the nonsense 
suppression state was maintained in [MC] and [C] containing strains but not in the 
[SUP35] containing strain. For the [SUP35] containing strain (stage III), [MC] was 
transformed in again, and [SUP35] was lost (stage IV), yet the nonsense suppression was 




4-3-4 [MCS+] is infectious 
 
 
Prion is an infectious agent which can convert the non-prion form of the same protein 
into the prion form. In order to test whether the [MCS+] state is infectious, the yeast 
extract transfection assay was performed.  Cell lysate from the [MCS+] strain was 
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[MCS+] cell extract was transfected into an isogenic [m s-] strain. 1% [mcs-] cells became 
Ade+ after transfection and were also GuHCl curable. In contrast, no [mcs-] cells became 
Ade+ if transfected with water instead of [MCS+] extract. Notably, the transfection rate of 
[MCS+] was much less than that of [PSI+], indicating a weaker infectivity.            
         
[MCS+]                [mcs-]             700          7                    1%
H2O                   [mcs-]             260          0                    0
GT81-1C              GT17              80            6               7.5%
H2O                   GT17             180           0            0
Transfection Recipient       Transfectants % Transfection
Donor                                   Total #      Ade+                           rate
Table 4-3. [MCS+] cell extract transfection result
(GT81-1C: [PSI+PIN+], GT17: [psi-pin-])
                     
 
4-3-5 Effects of the Hsp104 chaperone on [MCS+]         
 
As mentioned above, the Hsp104 chaperone is required for yeast prion propagation. 
Transient overproduction of Hsp104 cures the [PSI+] prion but not [PIN+] or [URE3]. In 
this study, we also tested the effects of Hsp104 on [MCS+]. In order to test if Hsp104 is 
required for [MCS+] propagation, we disrupted the HSP104 coding gene in the [MCS+] 
strain (described in the methods section), so that no functional Hsp104 was produced. 
Strikingly, the nonsense suppression phenotype still ex sted in the HSP104-disrupted 
strain (Figure 4-4 A). The nonsense suppression could still be cured by GuHCl; however, 
the curing efficiency was decreased dramatically when compared with that of the 
95                                                                                                                                                     
 
 
HSP104 wildtype strain. It was suggested that GuHCl cures y ast prions by inactivating 
Hsp104 activity, which would eliminate prion propagation (Glover et al., 2009). However, 
[MCS+] was GuHCl curable, but not Hsp104 dependent, indicating a potentially different, 
but not a necessarily exclusive system for propagation. GuHCl can still cure HSP104 
disrupted strain with less efficiency, indicating tha  GuHCl can possibly inactive other 
propagating factors, but not as efficiently as Hsp104.  
 
Additionally, Hsp104 was transiently overproduced in a [MCS+] strain by transforming in 
the Hsp104-overproducing plasmid pLH105 and by then eliminating this plasmid from 
the strain. Notably, the nonsense suppression phenotype f [MCS+] was cured following 
Hsp104 overproduction (Figure 4-4 B). This result is interesting becausepropagation of 
[MCS+] was not Hsp104-dependent, but excess Hsp104 did eliminate [MCS+] from the 
strain. This result indicates that Hsp104 still interacts with the prion factor of [MCS+] and 
functions to disaggregate this prion.      
   
               
[MCS+]     hsp104∆
GuHCl
curing rate 72%        11%





Figure 4-4. Effects of the Hsp104 chaperone on [MCS+]. hsp104∆ refers to the [MCS+] 
strain having the genomic HSP104 gene disrupted. Nonsense suppression was tested on –
Ade media. A- Nonsense suppression was not eliminated in the [MCS+] strain with the 
genomic HSP104 gene disrupted. The suppression was eliminated from the hsp104∆ 
strain by GuHCl, while the curing rate was decreased when compared with that of the 
wild type strain. B- Transient overproduction of Hsp104 eliminated the nonsense 
suppression of [MCS+].   
 





4-3-6 Analysis of the [MCS+] prion factorby “agarose trapping” 
 
 
As described in chapter 3, amyloid formed by prion can be isolated by the “agarose 
trapping” assay and can then be identified by MS. We analyzed the cell lysate extracted 
from a [MCS+] strain using the “agarose trapping” assay. The sample trapped in agarose 
gel was both tested by flamingo staining and was then analyzed by MS. There were no 
apparent protein bands visualized by the flamingo strain, indicating less abundance of the 
proteins trapped.  MS analysis confirmed that no prteins trapped were abundant. The 
detected proteins are listed in table 4-4. Ygp1, Tdh1/2/3 and Pma1 were also detected as 
backgrounds or contaminations from other non-[MCS+] samples (Table 3-1, 3-2). There 
are 2 proteins found to be specific to the [MCS+] sample as compared with the pre-boiled 
sample of [MCS+] or the sample from the GuHCl-cured strain. However, the abundances 
of these were too low to be confirmed as being “trapped”.   
 
Table 4-4. Proteins detected in agarose trap from [MCS+] sample
Protein Description Size, kD
Ygp1              Cell wall-related secretory glycoprotein                                    37 (>200 when glycosylated)
Tdh1/2/3        Trioso-phosphate dehydrogenase 37 
Ecm33           GPI-anchored protein of unknown function                            44
Pma1             Plasma membrane H+-ATPase 100
([MCS+] specific, less abundant)
Fks1             Glucan synthase, cell wall synthesis and maintenance              215





4-3-7 A nuclear element is involved in [MCS+] 





[MCS+] is not cytoducible 
 
Unlike chromosomal elements, yeast prions are cytoplasmic elements that can be 
transmitted to other cells via cytoplasmic transfer (cytoduction). We tested the 
cytoduction effect of [MCS+] by mating a [MCS+] strain with the cytoduction recipient 
strain GT1123 which is [mcs-] and expresses only Sup35MC. Mixed with the cytoplasmic 
materials from the [MCS+] strain, the cytoductants were tested on –Ade media for 
nonsense suppression. The result showed that none of th 226 cytoductants acquired the 
nonsense suppression phenotype from [MCS+]. This indicates that [MCS+] may not 
simply be caused by a cytoplasmic prion factor as is the case for other known yeast 
prions.    
  
[MCS+] is dominant and follows a pattern of Mendelian inheritance  
 
Prions display patterns of non-Mendelian inheritance during meiosis. We checked the 
inheritance of [MCS+] by mating a [MCS+] strain with a [mcs-] strain (expressing only 
Sup35MC) having an opposite mating type. The diploid strain was induced to sporulate, 
and the 4 spores within a single tetrad were dissected and analyzed phenotypically. For a 
given trait, the typical Mendelian inheritance will present as a 2:2 segregation rate. In 
contrast, prions follow a non-Mendelian type of inheritance; instead, all progenyinherit 
the prion state, showing a 4:0 segregation rate.  By mating a [MCS+] strain with a [mcs-] 
strain, the diploid strain showed a nonsense suppression phenotype (data not shown), 
indicating that [MCS+] is dominant. Then, a tetrad analysis was performed for the diploid 
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strain. Strikingly, the [MCS+] strain showed a 2:2 segregation rate (Table 4-5), different 
from classical prion-inheritance. Overall, the Mendlian inheritance of [MCS+] indicated 
the existence of a nuclear element. This is particularly interesting since the [MCS+] prion-
like state is not simply due to a conformational change of a specific protein; it is also 
controlled by a nuclear element.  Since Sup45 is another translation termination factor 
working together with Sup35, dysfunction of this protein may lead to nonsense 
suppression. We sequenced the SUP45 gene in the genome of the [MCS+] strain, and 
there were no mutations present in the gene. Some oth r nuclear factor must be 
responsible for the [MCS+] phenotype.  
 
Diploid                     No. of full tetrads with Ade+: Ade- segregation           Total No. of spores 
4:0          3:1         2:2 1:3          0:4                  Ade+ Ade-
[MCS+]/[mcs-]             0             1           11              1       0                     103              114
[mcs-]/[mcs-]               0             0             0              0    12                      0                   81 





4-3-8 Synthetic Genetic Array (SGA) screening for the nuclear factor responsible for 
[MCS+] 
 
Synthetic lethality occurs when the combination of two mutations leads to an inviable 
organism. Mutants that are defective in the same essential pathway or in parallel 
nonessential pathways often display synthetic lethaity (Tong et al., 2001).  Dr. Boone’s 
lab developed a synthetic genetic array (SGA) method o screen “synthetic lethal” double 
genetic mutations (Tong et al., 2001; Tong et al., 2006). They did this by incorporating a 
target gene deletion with ~5000 viable gene deletion mutants (about 80% of all yeast 
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genes) in S. cerevisiae. Since [MCS+] causes nonsense suppression, the nuclear element 
of [MCS+] (presumably a gene mutation) may also involve a translation termination 
process. As translation termination is an essential process, it is likely that a deletion of the 
gene will result in lethality or sublethality. Since [MCS+] only appears in the absence of 
Sup35N, a SGA screening in the SUP35N-deleted strain may provide us with a series of 
candidates for the nuclear element responsible for [MCS+].  
 
The SGA screening was performed by Dr Boone’s lab at the University of Toronto. The 
SUP35 gene was deleted in the starting strain which contained a Sup35MC-expressing 
plasmid. 145 double deletions were screened for synthetic lethality at different levels. 
Then, we performed a small-scale SGA screening within t e 145 candidate deletions 
following the protocol described in ref. Tong et al., 2006. We used another starting strain 
that expressed full-length Sup35as a control.. Ultima ely, we found 6 double mutants 
with significant synthetic lethality effects in the strain expressing only Sup35MC, but 
with little or no lethality for the strain expressing Sup35 (Figure 4-5). The other mutants 
showed mild to no lethality, or the lethality wascomparable between the strains 
expressing Sup35MC or full length Sup35. The genes responsible for synthetic lethality 
are listed in Table 4- 6. These results suggested that the prion domain of Sup35 may be 
involved in various processes that regulate cellular functions.  In order to further target 
the nuclear element of [MCS+], the nonsense suppression of the candidate double mutants 
can be checked by generating an ade1 nonsense mutation in the strains.     
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Figure 4-5. Detection of the synthetic lethality effect. The haploid spore with a double 
deletion of SUP35 and the target gene (XXX) which contains a SUP35MC or full length 
Sup35 protein-expressing plasmid, was selected throug  the SGA screening. If the 
deleted gene had a synthetic lethal effect in the absence of Sup35N, it could be detected 
by weaker growth on the selective medium (e.g. gsh1∆, panel I) as compared with the 
strain expressing full-length Sup35 (panel II).  If the deleted gene had no synthetic lethal 
effect in the absence of Sup35N, then there was no difference between the growths in 




Table 4-6. List of genes with synthetic lethal effect in the absence of Sup35N
Gene                                  Description 
SUR4              Elongase, involved in fatty acid and sphingolipid biosynthesis 
GSH1             Gamma glutamylcysteine synthetase, involved in glutathione biosynthesis
CDC73           Component of the Paf1p complex, modulates the activity of RNA polymerases I and II
SWS2             Putative mitochondrial ribosomal protein, participates in controlling sporulation efficiency 
MKS1             Transcriptional regulator, involved in Ras-CAMP and lysine synthesis and nitrogen regulation






We found a prion-like state termed [MCS+] that causes nonsense suppression in the 
absence of the Sup35 prion domain. [MCS+] showed some prion-like properties. 
[MCS+] could also be cured by the prion-eliminating agent GuHCl or by transient 
overproduction of Hsp104, suggesting the existence of a prion-like factor. However, 
101                                                                                                                                                     
 
 
[MCS+] followed a Mendelian pattern of inheritance, indicat ng the involvement of a 
nuclear element. It is possible that the prion factor and the nuclear factor coexist, and 
both may contribute to [MCS+]; alternatively, the prion factor may be triggered by the 
nuclear factor. Thus, the prion factor would contribute to the prion-like properties of 
[MCS+].   Interestingly, plasmid shuffle results showed that [MCS+] existed in a strain 
expressing only Sup35C, suggesting that the Sup35M region did not significantly 
affect [MCS+]. However, the [MCS+] phenotype disappeared in the presence of full-
length Sup35, and nonsense suppression was partially restored once Sup35 was 
removed from the cell.  The presence of Sup35N may interact with the [MCS+] prion 
factor and inhibit or “mask” it, resulting in a phenotypic elimination. However, the 
nuclear element of [MCS+] would still exist, and the prion factor would be recovered 
by the nuclear factor upon removal of Sup35N.  The inf ctivity of [MCS+] was 
confirmed by transfection of yeast extract. However, our result also showed that 
[MCS+] cannot be transmitted by cytoplasm transfer (cytoduction). The total yeast 
extract may contain some nuclear materials, so the prion factor and the nuclear factor 
responsible for [MCS+] would have a chance to be transferred to the recipi nt cell. In 
contrast, there is only transfer of cytoplasm in cytoduction, so the nuclear factor can 
be transmitted to the recipient. Hsp104 was shown to modulate [MCS+] propagation 
and excess Hsp104 cured [MCS+]. However, the propagation of [MCS+] was not 
Hsp104-dependent and [MCS+] could be stably maintained by a HSP104 deleted 
strain.   
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Interestingly, a new prion-like state termed [NSI+] was recently described and only 
existed in the absence of Sup35N (Saifitdinova et al., 2010). [NSI+] and [MCS+] share 
several common features; notably, they both cause nonsense suppression that is 
curable by GuHCl. Introduction of full-length Sup35 eliminates the prion phenotype, 
and for both, the prion phenotype can be recovered by removal of the Sup35 protein. 
However, [NSI+] follows a non-Mendelian pattern of inheritance and can be 
transmitted by cytoduction, indicating that no nuclear element is involved.  
Additionally, Hsp104 is required for [NSI+] propagation, while [MCS+] propagation is 
Hsp104-independent. The prion factors from [NSI+] and [MCS+] may, in fact, 
overlap. A study of one phenomenon may shed light on he other. Ultimately, the 
identification and further characterization of the [MCS+] and the [NSI+] factors will 
help us understand prion-related phenomena, as well as nonsense suppression 
epigenetic control.  
 
 
4-5 Conclusions:  
 
• [MCS+] causes nonsense suppression curable by GuHCl. 
 
• The [MCS+] phenotype disappeared in the presence of Sup35N.  
 
• [MCS+] is infectious.  
 
• Propagation of [MCS+] is not Hsp104-dependant.  
 
• [MCS+] follows a Mendelian pattern of inheritance.  
















origin Source Provided by 
S288c 
California, 
USA Rotting fig Haber JE 
YS2 Australia Baker strain Bell P 
YS4 Netherlands Baker strain Bell P 
YS9 Singapore Baker strain Bell P 
PGL-1 
PGL-2 NA 




































S. cerevisiae strains of various origins 
(No [PIN+], [PSI+] or [URE3] prions detected with “gel boiling” assay) 
 
Strain Geographic origin Source Provided by 
SK1 USA Soil Haber JE 
W303 
Created by Rothstein R 
by multiple crossing NA EUROFAN 
Y55 France Grape Haber JE 
322134S 
Royal Victoria Infirmary, 
Newcastle, UK Clinical isolate (Throat) Mackenzie D 
378604X 
Royal Victoria Infirmary, 
Newcastle, UK Clinical isolate (Sputum) Mackenzie D 
273614N 
Royal Victoria Infirmary, 
Newcastle, UK Clinical isolate (Fecal) Mackenzie D 
UWOPS83-787.3 
Great Inagua Island, 
Bahamas Fruit, Opuntia stricta Lachance M 
UWOPS87-242.1 
Puhelu Road, Maui, 
Hawaii, 
Cladode, Opuntia 
megacantha Lachance M 
L-1374 Cauquenes, Chile 
Fermentation from must  
pais Martinez C 
L-1528 Cauquenes, Chile 
Fermentation from must 
Cabernet Martinez C 
BC187 
Napa Valley, Bisson L, 
USA Barrel fermentation Gerke J 
DBVPG1106 Australia Grapes Vaughan A 
DBVPG1373 Netherlands Soil Vaughan A 
DBVPG6765 Unknown Unknown Vaughan A 
YIIc17_E5 Sauternes, France Wine Souciet JL 
DBVPG6040 Netherlands Fermenting fruit juice Vaughan A 
NCYC361 Ireland 
Beer spoilage strain from 
wort NCYC 
DBVPG1788 Turku, Finland Soil Vaughan A 




Ospedali Riuniti di 
Bergamo, Italy 
Isolated from vagina of 
patient suffering from 
vaginitis McCusker J 





Malaysia, Nectar, Bertram palm Lachance M 
UWOPS05-217.3 
Telok Senangin, 
Malaysia, Nectar, Bertram palm Lachance M 
UWOPS05-227.2 
Telok Senangin, 
Malaysia, Trigona spp (Stingless bee) Lachance M 
K11 Japan Shochu sake strain Fay J 
Y9 Indonesia Ragi (similar to sake wine) Fay J 
Y12 Ivory Coast Palm wine strain Fay J 
YPS606 Pennsylvania, USA, Bark of Q. rubra Gerke J 
YPS128 Pennsylvania, USA, Soil beneath Q. alba Sniegowski P 
NCYC110 West Africa 
Ginger beer from 
Z.officinale NCYC 
DBVPG6044 West Africa 
Bili wine, from Osbeckia 


























  S. paradoxus strains of various origins 
(No [PIN+], [PSI+] or [URE3] prions detected by “gel boiling” assay) 
 
STRAIN Geographic origin Source Provided by 
Q31.4 
Windsor Great Park, 




Windsor Great Park, 




Windsor Great Park, 




Windsor Great Park, 




Windsor Great Park, 




Windsor Great Park, 




Windsor Great Park, 




Windsor Great Park, 
UK Bark of Quercus spp 
Koufopanou 
V 
S36.7 Silwood Park, UK, Bark of Quercus spp 
Koufopanou 
V 
T21.4 Silwood Park, UK, Bark of Quercus spp 
Koufopanou 
V 
W7 Silwood Park, UK, Bark of Quercus spp 
Koufopanou 
V 
Y6.5 Silwood Park, UK, Bark of Quercus spp 
Koufopanou 
V 
Y7 Silwood Park, UK, Bark of Quercus spp 
Koufopanou 
V 
Y8.1 Silwood Park, UK, Bark of Quercus spp 
Koufopanou 
V 
Y8.5 Silwood Park, UK, Bark of Quercus spp 
Koufopanou 
V 
Y9.6 Silwood Park, UK, Bark of Quercus spp 
Koufopanou 
V 
Z1 Silwood Park, UK, Bark of Quercus spp 
Koufopanou 
V 
Z1.1 Silwood Park, UK, Bark of Quercus spp 
Koufopanou 
V 
N-17 Tartastan, Russia Exudate of Q. robur Naumov G 
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CBS432 Moscow area, Russia Bark of Quercus spp Naumov G 
CBS5829 Denmark Mor soil, pH3.6 Naumov G 
DBVPG4650 Marche, Italy Fossilized guano in a cavern Vaughan A 
KPN3828 
Novosibirsk, Siberia, 
Russia Bark of Q. robur Iurkow A 
KPN3829 
Novosibirsk, Siberia, 
Russia, Bark of Q. robur Iurkow A 
N-43 Vladivostok, Russia Exudate of Q. mongolica Naumov G 
N-44 Ternei, Russia Exudate of Q. mongolica Naumov G 
N-45 Ternei, Russia Exudate of Q. mongolica Naumov G 
IFO1804 Japan Bark of Quercus spp Pérez-Ortín J 
YPS138 Pennsylvania, USA Soil beneath Q. velutina Sniegowski P 
DBVPG6304 
Yosemite, California, 
USA Drosophila pseudoobscura Vaughan A 
A4 
Mont St-Hilaire, 









Catalao point, Rio de 
Janeiro, Brazil Drosophila spp Naumov G 
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